PYRAZOLO FUSED RING COMPOUNDS AND USES THEREOF

Pyrazolo fused ring compounds provide selective inhibition of TYK2 and JAK1/JAK2, effectively treating psoriasis and inflammatory bowel disease by targeting the JAK-STAT pathway with minimal side effects.

JP2024544554AActive Publication Date: 2024-12-03CMS RESEARCH & DEVELOPMENT PTE LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024528439
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-01
Filing Date
2022-11-09
Publication Date
2024-12-03
Estimated Expiration
2042-11-09

AI Technical Summary

Technical Problem

Current treatments for inflammatory and autoimmune diseases such as psoriasis and inflammatory bowel disease lack specificity in targeting the Janus kinase (JAK) pathway, particularly the TYK2 and JAK2 members, leading to non-selective inhibition and potential off-target effects.

Method used

Development of pyrazolo fused ring compounds that selectively inhibit TYK2 and/or JAK1 and/or JAK2, offering a targeted approach to disrupt the JAK-STAT signaling pathway and reduce inflammation without significant impact on animal body weight.

Benefits of technology

The compounds demonstrate good oral bioavailability and inhibit ear thickness in mouse models, reducing swelling and improving scores in psoriasis and inflammatory bowel disease models while maintaining animal health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544554000001_ABST
    Figure 2024544554000001_ABST
Patent Text Reader

Abstract

A series of pyrazolo fused ring compounds and uses thereof are disclosed, specifically, compounds represented by formula (IV) and pharma- ceutically acceptable salts thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] [CITATION OF RELATED APPLICATIONS]

[0002] This application claims priority to and benefits from Chinese Invention Patent Application No. 202111342790.8, filed with the China National Intellectual Property Office on November 12, 2021, and Chinese Invention Patent Application No. 202211358879.8, filed with the China National Intellectual Property Office on November 1, 2021, the entire contents of which are incorporated herein by reference in their entirety.

[0003] The present invention relates to a series of pyrazolo fused ring compounds and uses thereof, in particular to compounds represented by formula (IV) and pharma- ceutically acceptable salts thereof: [Background technology]

[0004] Janus kinases (JAKs) are cytoplasmic tyrosine kinases that transmit cytokine signals from membrane receptors to STAT transcription factors. The JAK family consists of four members: JAK1, JAK2, JAK3, and TYK2. The JAK-STAT pathway transmits extracellular signals from various cytokines, growth factors, and hormones to the nucleus and is responsible for the expression of thousands of protein-coding genes. The JAK-STAT pathway is involved in the following steps to convert extracellular signals into transcriptional responses: 1) When cell surface cytokine receptors bind to their respective cytokine ligands, a conformational change occurs leading to dimerization of the receptor molecules, which brings the receptor-bound JAK kinases into close proximity with each other and activates them through interactive tyrosine phosphorylation. 2) Activation of JAKs catalyzes the phosphorylation of tyrosine residues on the receptors, and these phosphorylated tyrosine sites then form "docking sites" with the surrounding amino acid sequences, and simultaneously, STAT proteins containing SH2 structural domains are recruited to these "docking sites." 3) Finally, the kinase JAK catalyzes the phosphorylation modification of receptor-bound STAT proteins, and the activated STAT proteins leave the receptor to form dimers and then translocate to the nucleus to regulate the transcription of specific genes. JAK-STAT intracellular signaling applies to interferons, most interleukins, and various cytokines and endocrine factors such as EPO, TPO, GH, OSM, LIF, CNTF, GM-CSF, and PRL (Vainchenker WE T al. (2008)).

[0005] Different JAK family members selectively bind to different cytokine receptors, conferring signal transduction specificity and thereby exerting different physiological effects, and this selective mechanism of action allows JAK inhibitors to be applied to diseases with relative specificity. TYK2 is a member of the JAK kinase family and is an important mediator of inflammatory cytokine signal transduction, such as IL-12, IL-23, and type I interferon. These cytokines are associated with the pathogenesis of various inflammatory and autoimmune diseases, such as psoriasis, inflammatory bowel disease (IBD), and systemic lupus erythematosus (SLE). Therefore, the development of an inhibitor with high inhibitory activity against TYK2 and a given inhibitory activity against JAK2 and JAK1 can maximally inhibit the formation of intracellular heterodimers of TYK2 with JAK2 and JAK1, block the signal transduction pathway, and block the signal transduction of inflammatory cytokines IL-12, IL-23, and type I interferon to treat certain diseases. Summary of the Invention

[0006] The present invention provides a compound represented by formula (IV) or a pharma- ceutically acceptable salt thereof.

[0007] [ka]

[0008] however, R A is selected from H, and R B teeth,

[0009] [ka]

[0010] is selected from Or, R A and R B are the carbon atoms to which they are connected

[0011] [ka]

[0012] Forming Ring A is C 5-8 cycloalkyl; Ring B is C 5-12 cycloalkyl or 5- to 12-membered heterocycloalkyl; R1 is H, C 1-3 alkyl selected from -SO2-, CN and -CH2CN, 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; R2 is H and C 1-3 alkyl, 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; R3 is H, NH2, halogen, OH, CN and C 1-3 alkyl, 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; T2 is selected from CH and N.

[0013] In some embodiments of the present invention, Ring A is

[0014] [ka]

[0015] is selected from.

[0016] In some embodiments of the present invention, Ring B is

[0017] [ka]

[0018] is selected from Where L1 is -(CH2) m -, wherein -(CH2) m- is optionally substituted by 1, 2 or 3 halogens; L2 is -(CH2) n -, wherein -(CH2) n - is optionally substituted by 1, 2 or 3 halogens; m and n are each independently selected from 1, 2, and 3; T1 is selected from CH and N; R1 is as defined in formula (IV).

[0019] In some embodiments of the present invention, the compound represented by formula (IV) or a pharma- ceutically acceptable salt thereof is selected from structures represented by formulas (IV-1) and (IIV-2).

[0020] [ka]

[0021] wherein R1, R2, R3, T2, ring A and ring B are as defined in formula (IV).

[0022] The present invention further provides a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof.

[0023] [ka]

[0024] however, R1 is H, C 1-3 alkyl selected from -SO2-, CN and -CH2CN, 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; R2 is H and C 1-3 alkyl, 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; R3 is H, NH2, halogen, OH, CN and C 1-3 alkyl,1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; L1 is -(CH2) m -, wherein -(CH2) m - is optionally substituted by 1, 2 or 3 halogens; L2 is -(CH2) n -, wherein -(CH2) n - is optionally substituted by 1, 2 or 3 halogens; m and n are each independently selected from 1, 2, and 3; T1 is selected from CH and N; T2 is selected from CH and N.

[0025] In some embodiments of the present invention, R1 is H, C 1-3 alkyl selected from -SO2-, CN and -CH2CN, 1-3 The alkyl is optionally substituted with 1, 2 or 3 F, and other variables are as defined herein.

[0026] In some embodiments of the present invention, R1 is selected from H, CF3SO2-, CN, and -CH2CN, and other variables are as defined herein.

[0027] In some embodiments of the present invention, R2 is selected from H and CH3, and other variables are as defined herein.

[0028] In some embodiments of the present invention, R3 is selected from H and NH2, and other variables are as defined herein.

[0029] In some embodiments of the present invention, L1 is selected from -CH2- and -CH2CH2-, wherein said -CH2- and -CH2CH2- are optionally substituted by 1, 2 or 3 F, and other variables are as defined herein.

[0030] In some embodiments of the present invention, L1 is selected from -CH2- and -CH2CH2-, and all other variables are as defined herein.

[0031] In some embodiments of the present invention, L2 is selected from -CH2- and -CH2CH2-, wherein -CH2- and -CH2CH2- are optionally substituted by 1, 2 or 3 F, and other variables are as defined herein.

[0032] In some embodiments of the present invention, L2 is selected from -CH2- and -CH2CH2-, with other variables as defined herein.

[0033] In some embodiments of the invention, the structural fragment

[0034] [ka]

[0035] is selected from acridinyl, cyclobutyl, tetrahydropyrrolyl, piperidinyl, and cyclohexyl, and the other variables are as defined herein.

[0036] In some embodiments of the invention, the structural fragment

[0037] [ka]

[0038] and the other variables are as defined herein.

[0039] In some aspects of the invention, the compound, or a pharma- ceutically acceptable salt thereof, is selected from the formula:

[0040] [ka]

[0041] In the above, R1, R2, R3, T1, T2, m and n are as defined in the present invention.

[0042] The present invention further provides a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof.

[0043] [ka]

[0044] however, R1 is H, C 1-3 alkyl selected from -SO2-, CN and -CH2CN, 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; R2 is selected from H and CH3; R3 is selected from H and NH2; L1 is -(CH2) m -, wherein -(CH2) m - is optionally substituted by 1, 2 or 3 halogens; L2 is -(CH2) n -, wherein -(CH2) n - is optionally substituted by 1, 2 or 3 halogens; m and n are each independently selected from 1, 2, and 3; T1 is selected from CH and N; T2 is selected from CH and N.

[0045] Some aspects of the invention are further formed by any combination of the variables listed above.

[0046] The present invention further provides a compound selected from the formula: or a pharma- ceutically acceptable salt thereof.

[0047] [ka]

[0048] The present invention further provides a compound selected from the formula: or a pharma- ceutically acceptable salt thereof.

[0049] [ka]

[0050] The invention further provides the use of the above compound, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of psoriasis and / or inflammatory bowel disease.

[0051] The present invention further provides the following test method.

[0052] Test method 1: Anti-inflammatory effect test in type II collagen-induced mouse toe swelling model Experimental objective: To establish a mouse arthritis model by subcutaneously injecting type II collagen into the tail base of DBA / 1 mice, and to use this model to study the anti-inflammatory effects of test samples on mouse toe swelling model induced by type II collagen.

[0053] Experimental Method 1.1 Preparation of reagents Take 1.43 mL of acetic acid and add 500 mL of ultrapure water to produce a 0.05 mol L-1 acetic acid solution.

[0054] Weigh out an appropriate amount of type II collagen, add an appropriate amount of 0.05 mol L-1 acetic acid solution to the glass bottle containing the collagen, and invert the bottle to completely dissolve the collagen, obtaining a collagen solution with a concentration of 2.0 mg mL-1. Place the same volume of Freund's complete adjuvant or Freund's incomplete adjuvant (Freund's complete adjuvant is used for the first immunization, and Freund's incomplete adjuvant is used for the second booster immunization) on ice, add the collagen solution drop by drop, and simultaneously stir slowly with a magnetic stirrer to obtain a uniform emulsion. The criterion for judgment is whether the emulsion spreads when dropped onto the water surface.

[0055] 1.2 Preparation of animal models On experiment D1, absorb the collagen emulsion using a 1 mL syringe and subcutaneously inject it into the mouse tail base, injecting 100 μL (1 mg mL-1) into each animal to immunize a total of 170 animals (the remaining 10 animals are not immunized and serve as a normal control group). Three weeks after immunization (D21), perform a booster immunization by injecting 100 μL / animal (1 mg mL-1). Regularly observe the condition of the animals and the swelling induction state of the toes, and if the thickness increase rate of the left and right hind paws is 20% or more, it is judged as successful immunization. Score the degree of swelling of all four paws at the same time.

[0056] Scoring rules for paw swelling are as follows: 1 point: Mild redness and swelling in a single area of ​​the tarsus or ankle; 2 points: Mild redness and swelling from the ankle to the tarsus. 3 points: Moderate redness and swelling from the ankle to the metatarsal area. 4 points: Severe redness, swelling or stiffness in the joints, soles of the feet and toes. The maximum score for any one limb is 4 points, with a maximum score per mouse being 16 points. Paw thickness measurement: Measure the thickness of the mouse paw or ankle using calipers and import the measurement data into Excel.

[0057] 1.3 Animal Grouping and Treatment Screen the model animals based on the animal's weight, ankle thickness, paw swelling score, and other indicators, as well as the animal's overall condition, and exclude animals with unsuitable indicators such as weight, ankle thickness, and paw swelling score. Select animals with a significant and similar increase in ankle thickness, randomly divide them into groups, and begin administration for a total of 14 days. Set up one general group (without immunization) and leave it untreated.

[0058] 1.4 Clinical observation and index measurement After the second immunization, observe the condition of the animals and the swelling of the toes daily (once a day), and start monitoring the limb scores after most of the immunized animals show significant swelling of the toes. After the start of administration, observe the condition of the animals daily (once a day), record the body weight twice a week, and simultaneously perform the scoring of the animal limbs (twice a week) and the measurement of the ankle joint thickness (twice a week). Effect of the Invention

[0059] [Technical effect] The compounds of the present invention show good selective inhibition against TYK2 and / or JAK1 and / or JAK2 in the in vitro activity test of four kinase subtypes, JAK1, JAK2, JAK3 and TYK2. In mice, all of them have good oral bioavailability and higher exposure, which is beneficial for producing good drug effects in vivo. The compounds of the present invention do not significantly affect the body weight of animals in IL-23-induced C57BL / 6 mouse ear epidermis abnormality model, can inhibit the increase in the thickness of modeled ears of mice to various degrees, and all of them show a good dose-response relationship for the effect of reducing the weight of modeled ears of animals. Oral administration of the compounds of the present invention can significantly improve the degree of swelling of mouse paws, improve the score and relative score, and at the same time, does not significantly affect the body weight of animals. [Brief description of the drawings]

[0060] [Figure 1] FIG. 1 is an ellipse diagram of the conformation of compound 1. [Diagram 2] FIG. 1 is a unit cell stacking diagram of compound 1 along the b-axis direction. [Diagram 3] FIG. 1 is an absolute configuration diagram of compound 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0061] [Definitions and Explanations] Unless otherwise stated, the following terms and phrases used herein have the following meanings. A particular term or phrase, unless otherwise defined, should be understood as being of ordinary definition, not indefinite or unclear. When a trade name is mentioned in this specification, it refers to the corresponding product or its active ingredient.

[0062] As used herein, the term "pharmacologically acceptable" refers to those compounds, materials, compositions and / or dosage forms which are within the scope of sound medical judgment, suitable for contact with human and animal tissues, without significant toxicity, irritation, allergic response or other problem or complication, and consistent with a reasonable benefit / risk ratio.

[0063] The term "pharmaceutical acceptable salt" refers to a salt of a compound of the present invention, which is prepared with a relatively non-toxic acid or base with a compound having certain substituents found in the present invention. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral forms of these compounds with a sufficient amount of base in a single solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts, or similar salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral forms of these compounds with a sufficient amount of acid in a single solution or in a suitable inert solvent. Some specific compounds of the present invention contain basic and acidic functional groups, and therefore can be converted into any base addition salt or acid addition salt.

[0064] The pharma- ceutically acceptable salts of the present invention can be synthesized in a conventional manner from the parent compound which contains an acidic or basic group. Typically, such salts are prepared by reacting the compound in its free acid or base form with a stoichiometric amount of the appropriate base or acid in water or an organic solvent, or a mixture of both.

[0065] Unless otherwise specified, the term "isomer" is intended to include geometric isomers, cis-trans isomers, stereoisomers, enantiomers, optical isomers, enantiomers and tautomers.

[0066] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, such as mixtures enriched in enantiomers or non-enantiomers, and all such mixtures are within the scope of the present invention. Other asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers and mixtures thereof are both within the scope of the present invention.

[0067] Unless otherwise stated, the terms "enantiomers" or "optical isomers" refer to stereoisomers that are mirror images of one another.

[0068] Unless otherwise stated, the term "cis-trans isomers" or "geometric isomers" refers to isomers that are due to the inability to freely rotate about double bonds or single bonds of ring carbon atoms.

[0069] Unless otherwise explained, the term "diastereomer" refers to stereoisomers whose molecules have two or more centers of chirality and whose molecules are not mirror-images of each other.

[0070] Unless otherwise specified, "(+)" means dextrorotatory, "(-)" means levorotatory, and "(±)" means racemic.

[0071] [ka]

[0072] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, such as mixtures enriched in enantiomers or non-enantiomers, and all such mixtures are within the scope of the present invention. Other asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers and mixtures thereof are both within the scope of the present invention.

[0073] Unless otherwise stated, the term "tautomer" or "tautomeric form" refers to isomers of different functional groups that are in dynamic equilibrium and can be rapidly interconverted at room temperature. Tautomers can reach chemical equilibrium of tautomers when possible (e.g., in solution). For example, proton tautomers (also called prototropic tautomers) include interconversions via the transfer of a proton, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions by rearrangement of some bond electrons. Among them, a specific example of keto-enol tautomerization is the interconversion between the two tautomers of pentane-2,4-dione and 4-hydroxy-3-penten-2-one.

[0074] Unless otherwise explained, the terms "enriched in one isomer," "isomer-enriched," "enriched in one enantiomer," or "enantiomer-enriched" mean that the amount of one isomer or enantiomer is less than 100% and that the amount of such isomer or enantiomer is 60% or more, or 70% or more, or 80% or more, or 90% or more, or 95% or more, or 96% or more, or 97% or more, or 98% or more, or 99% or more, or 99.5% or more, or 99.6% or more, or 99.7% or more, or 99.8% or more, or 99.9% or more.

[0075] Unless otherwise stated, the term "isomer excess" or "enantiomeric excess" refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, then the isomeric or enantiomeric excess (ee value) is 80%.

[0076] Optically active (R)- and (S)-isomers, as well as D- and L-isomers, can be prepared using asymmetric synthesis or chiral reagents or other conventional techniques. A single enantiomer of a compound of the invention can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary is resolved to provide the desired isolated enantiomer. Alternatively, if the molecule contains a basic (e.g., amino) or acidic (e.g., carboxyl) functional group, the diastereomeric salt can be formed with an appropriate optically active acid or base, and the diastereomers can be resolved by conventional methods known in the art, followed by recovery to provide the isolated enantiomers. Separation of enantiomers and diastereomers is also typically accomplished by chromatographic techniques using chiral stationary phases and any chemical derivatization techniques (e.g., carbamate formation from amines).

[0077] The compounds of the present invention may contain unnatural atomic isotopes at one or more atoms that constitute the compounds. For example, tritium ( 3 H), iodine-125( 125 I) or C-14( 14Compounds can be labeled with radioisotopes such as radioisotopes C). Also, for example, deuterium can be replaced with hydrogen to form deuterated drugs, where the bond formed between deuterium and carbon is stronger than the bond formed between normal hydrogen and carbon, and compared to non-deuterated drugs, deuterated drugs have the advantages of reduced toxic side effects, increased drug stability, improved therapeutic efficacy, and extended biological half-life of the drug. Conversion of the isotopic composition of the compounds of the invention, whether radioactive or not, is within the scope of the invention.

[0078] Unless otherwise defined, the term "C 1-3 "Alkyl" refers to a saturated hydrocarbon group consisting of 1 to 3 carbon atoms in a straight or branched chain. 1-3 Alkyl has C 1-2 and C. 2-3 Alkyl, which may be monovalent (e.g., methyl), divalent (e.g., methylene) and polyvalent (e.g., methine). 1-3 Examples of alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.

[0079] Unless otherwise defined, the terms "halogen" or "halo," by themselves or as part of another substituent, mean a fluorine, chlorine, bromine, or iodine atom.

[0080] Unless otherwise stated, "C 5-8 "Cycloalkyl" means a saturated and cyclic hydrocarbon group of 5 to 8 carbon atoms, including monocyclic and bicyclic rings, where bicyclic rings include spiro, fused and bridged rings. 5-8 Cycloalkyl is C 3-6 , C 3-5 , C 5-8 , C 5-7 , C 5-6 , C5, C6 or C7 cycloalkyl, which may be monovalent, divalent or polyvalent. 5-8 Examples of cycloalkyl include, but are not limited to, bicyclo[1.1.1]pentyl, norbornyl, and the like.

[0081] Unless otherwise stated, "C 5-12 "Cycloalkyl" means saturated and cyclic hydrocarbon groups of 5 to 12 carbon atoms, including monocyclic, bicyclic and tricyclic ring systems, where the bicyclic and tricyclic ring systems include spirocyclic, fused and bridged rings. 5-12 Cycloalkyl has C 5-10 , C 5-8 , C 5-6 cycloalkyl, which may be monovalent, divalent or polyvalent. 5-12 Examples of cycloalkyl include, but are not limited to, bicyclo[1.1.1]pentyl, norbornyl, [2.2.2]dicyclooctane, [4.4.0]dicyclodecane, and the like.

[0082] Unless otherwise defined, the term "5-12 membered heterocycloalkyl" by itself or in combination with other terms refers to a saturated cyclic group composed of 5 to 12 ring atoms, of which 1, 2, 3, and 4 ring atoms are independently selected from O, S, and N heteroatoms, and the remainder are carbon atoms, wherein the carbon atoms are optionally oxo-substituted, the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., NO and S(O)). P, p is 1 or 2). The 5-12 membered heterocycloalkyl includes monocyclic, bicyclic and tricyclic ring systems, where bicyclic and tricyclic ring systems include spiro rings, fused rings and bridged rings. Additionally, for the "5-12 membered heterocycloalkyl", a heteroatom can occupy the position of attachment of the heterocycloalkyl to the remainder of the molecule. The 5-12 membered heterocycloalkyl includes 5-10 membered, 5-8 membered, 5-6 membered, 5 membered and 6 membered heterocycloalkyl, etc. Illustrative examples of 5-12 membered heterocycloalkyl include, but are not limited to, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, and the like), tetrahydrofuranyl (including tetrahydrofuran-2-yl, and the like), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl, and 3-piperidinyl, and the like), piperazinyl (including 1-piperazinyl and 2-piperazinyl, and the like), morpholinyl (including 3-morpholinyl and 4-morpholinyl, and the like), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl, homopiperidinyl, or dioxepanyl, and the like.

[0083] The terms "optionally" and "optionally" refer to the event or circumstance described below that may, but does not necessarily, occur, and the description includes instances where the event or circumstance described does not occur.

[0084] The term "substituted" refers to the replacement of any one or more hydrogen atoms at a particular atom with a substituent, which may include deuterium and hydrogen variants, provided that the particular valence state is correct and the compound is stable after substitution. When the substituent is a keto group (i.e., =O), it means that two hydrogen atoms are replaced. Keto group substitution does not occur on aromatic groups. The term "optionally substituted" refers to either substituted or unsubstituted, and unless otherwise defined, the type and number of substituents are any that are chemically stable and feasible.

[0085] When any variable (e.g., R) occurs more than once in a composition or structure of a compound, its definition is independent in each occurrence. Thus, for example, if a group is substituted with 0-2 R, then said group is optionally substituted with up to 2 R, and each occurrence of R is independently optional. Also, combinations of substituents and / or variants thereof are permissible only if such combinations result in stable compounds.

[0086] When the number of linking groups is 0, for example, -(CRR)0- means that the linking group is a single bond.

[0087] When one of the variables is a single bond, the two groups it links are directly linked; for example, when L in ALZ represents a single bond, the structure is actually AZ.

[0088] The absence of a substituent indicates that the substituent is not present, e.g., the absence of X in AX indicates that the structure is actually A. If a recited linking group does not specify another linking direction, the linking direction is arbitrary, e.g.,

[0089] [ka]

[0090] In the formula, the linking group L is -MW-, and in this case, -MW- constitutes ring A and ring B in the same direction as the reading order from left to right.

[0091] [ka]

[0092] You can also construct rings A and B in the reverse order of reading from left to right.

[0093] [ka]

[0094] Combinations of the above linking groups, substituents and / or variables are permissible only if such combinations result in stable compounds.

[0095] The compounds of the present invention can be prepared by a variety of synthetic methods familiar to those skilled in the art, including the specific embodiments given below, embodiments in combination with other chemical synthetic methods, and equivalent alternative methods familiar to those skilled in the art, and preferred embodiments include, but are not limited to, the examples of the present invention.

[0096] The structure of the compound of the present invention can be confirmed by conventional methods known to those skilled in the art, and when the present invention relates to the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means of those skilled in the art. For example, single crystal X-ray diffraction (SXRD), the cultured single crystal is collected by Bruker D8 venture diffractometer, the light source is CuKα radiation, the scanning method is φ / ω scanning, after collecting the relevant data, the absolute configuration can be confirmed by direct method (Shelxs97) crystal structure analysis.

[0097] All the solvents used in the present invention can be obtained from commercial sources. The present invention uses the following abbreviations: aq stands for water; eq stands for equivalent; M stands for mol / L; DCM stands for dichloromethane; PE stands for petroleum ether; DMF stands for N,N-dimethylformamide; DMSO stands for dimethylsulfoxide; EtOAc stands for ethyl acetate; EtOH stands for ethanol; MeOH stands for methanol; CBz stands for benzoxycarbonyl, an amine protecting group; Boc stands for tert-butoxycarbonyl, an amine protecting group; rt stands for room temperature; O / N stands for running overnight; THF stands for tetrahydrofuran. represents;Boc2O represents di-tert-butyl dicarbonate;trifluoroacetic acid represents trifluoroacetic acid;DIPEA represents diisopropylethylamine;SOCl2 represents thionyl chloride;Xphos-Pd-G2 represents chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II);mp represents melting point;DBU represents 1,8-diazabicyclo[5.4.0]undecane-7-ene;BrettPhos Pd G3 represents (2-dicyclohexylphosphino)-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate.

[0098] Compounds are named according to conventional naming principles in the art or ChemDraw® software; for commercially available compounds, manufacturer's catalog names are used. EXAMPLES

[0099] The present invention will be specifically described below by way of examples, but is not intended to be an adverse restriction of the present invention. The present invention has been described in detail herein, and specific embodiments thereof have been disclosed. It is obvious to those skilled in the art that various changes and modifications can be made in the specific embodiments of the present invention without departing from the spirit and scope of the present invention.

[0100] Example 1 or 2

[0101] [ka]

[0102] Synthesis scheme:

[0103] [ka]

[0104] Step 1: Synthesis of Compound 1-2

[0105] Compound 1-1 (10g, 64.87mmol) was added to anhydrous DCM (100.00mL), and (COCl)2 (12.35g, 97.30mmol, 8.52mL) and DMF (474.13mg, 6.49mmol, 499.09μL) were added dropwise at 0-5℃, and the mixture was stirred at 0-5℃ for 1 hour under the protection of nitrogen gas. After the reaction was completed, the reaction solution was concentrated under reduced pressure to dryness, and anhydrous DCM (120.00mL) was further added, and the resulting solution was cooled to 0℃, and ammonia gas was continuously blown into the reaction system for 10 minutes, and then the temperature was raised to 25℃ and stirred for 30 minutes. The reaction solution was concentrated under reduced pressure to dryness, and the residue was purified by silica gel column chromatography (dichloromethane:methanol=10:1) to obtain compound 1-2. 1 HNMR(400MHz, CD3OD)δ 3.15-3.25 (m, 3 H), 2.90-3.05 (m, 2 H), 2.45-2.55 (m, 2 H), 2.25-2.40 (m, 2 H).

[0106] Step 2: Synthesis of compounds 1-3

[0107] Under the protection of nitrogen gas at 0-5°C, trifluoroacetic anhydride (18.87g, 89.83mmol, 12.49mL) and triethylamine (22.72g, 224.58mmol, 31.26mL) were added sequentially to a solution of compound 1-2 (6.88g, 44.92mmol) in dichloromethane (140mL), and then the reaction solution was stirred for 1 hour at 0-5°C. After the reaction was completed, water (300mL) was added, extracted with dichloromethane (150mL x 2), and the combined extracted solution was washed with saturated saline (200mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 1-3. 1 HNMR(400MHz,CD3OD)δ 3.05-3.35 (m, 5 H), 2.56-2.75 (m, 4 H).

[0108] Step 3: Synthesis of compounds 1-4

[0109] At 25°C under the protection of nitrogen gas, a solution of compound 1-3 (2.12g, 15.68mmol) in tetrahydrofuran (10.00mL) containing diethyl cyanomethylphosphonate (3.33g, 18.82mmol, 3.03mL), LiBr (2.04g, 23.53mmol, 590.56μL) and triethylamine (3.17g, 31.37mmol, 4.37mL) in tetrahydrofuran (20.00mL) was added. The resulting reaction solution was stirred at 25°C for 16 hours. After the reaction was completed, water (100.00mL) was added to the reaction material, which was then extracted with ethyl acetate (60mL x 2). The combined extraction solution was washed with saturated saline (80mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1 to 3:1) to obtain compound 1-4. 1 H NMR(400MHz, CDCl3)δ 5.13-5.75 (m, 1 H), 2.98-3.10 (m, 3 H), 2.88-2.96 (m, 2 H), 2.40-2.65 (m, 4 H).

[0110] Step 4: Synthesis of compounds 1-6

[0111] Under the protection of nitrogen gas at 25 ° C, DBU (4.58 g, 30.10 mmol, 4.54 mL) and compound 1-4 (2 g, 12.64 mmol) were added sequentially to a solution of compound 1-5 (2.34 g, 12.04 mmol) in acetonitrile (40.00 mL), and the mixture was stirred at 25 ° C for 16 hours. After the reaction was completed, the mixture was quenched with 1M KH2PO4 aqueous solution (100 mL), extracted with ethyl acetate (60 mL × 2), and the combined extract solution was washed with saturated saline (80 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10: 1 to 1: 1) to obtain compound 1-6. 1 H NMR(400MHz, CDCl3)δ 7.84 (s, 1H), 7.83 (s, 1H), 3.00-3.10 (m, 1H), 2.80-2.95 (m, 4H), 2.55-2.75 (m, 4H), 2.30-2.40 (m, 2H), 1.32 (s, 12 H).

[0112] Step 5: Synthesis of Compounds 1-8

[0113] Under the protection of nitrogen gas at 25° C., compound 1-7 (200 g, 1.43 mol), 2-chloroacetonitrile (118.52 g, 1.57 mol) and cesium carbonate (557.99 g, 1.71 mol) were added sequentially to DMF (1 L), and the resulting reaction solution was stirred for 16 hours at 25° C. After completion of the reaction, the reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to dryness, and the resulting crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 1-8. 1 H NMR(400MHz , CDCl3)δ 7.60(d, J = 2.0 Hz, 1 H), 6.92 (d, J = 2.0 Hz, 1 H), 5.54 (s, 2 H), 4.40 (q, J =7.2 Hz, 2 H), 1.41 (t, J =7.2 Hz, 3 H).

[0114] Step 6: Synthesis of Compounds 1-9

[0115] A mixture of compound 1-8 (65 g, 362.77 mmol), concentrated sulfuric acid (177.90 g, 1.81 mol) and trifluoroacetic acid (206.82 g, 1.81 mol, 134.30 mL) was stirred for 16 hours under the protection of nitrogen gas at 20 ° C. After the reaction was completed, it was concentrated under reduced pressure to remove excess trifluoroacetic acid, the residue was poured into ice, the resulting aqueous solution was extracted with ethyl acetate (150 mL × 6), the combined extract solution was neutralized with saturated aqueous sodium bicarbonate solution until no bubbles appeared, separated, the organic phase was washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound 1-9. 1 H NMR(400MHz , CDCl3)δ 7.57 (d, J = 2.0 Hz, 1 H), 6.90 (d, J = 2.0 Hz, 1 H), 6.25 (brs, 1 H), 5.87 (brs, 1 H), 5.25 (s, 2 H), 4.33 (q, J = 7.2 Hz, 2 H), 1.36 (t, J = 7.2 Hz, 3 H).

[0116] Step 7: Synthesis of Compounds 1-10

[0117] Under the protection of nitrogen gas, a solution of compound 1-9 (36.49 g, 185.05 mmol) in ethanol (600 mL) was added with a solution of t-BuOK (1 M, 370.10 mL), and the resulting mixture was heated to 70° C. and stirred for 16 hours. After the reaction was completed, the mixture was cooled to 20° C. and the pH was adjusted to 6 with concentrated hydrochloric acid. The resulting suspension was concentrated under reduced pressure and dried to obtain the crude product compound 1-10. 1 H NMR(400MHz, DMSO-d6)δ 11.82 (brs, 1H), 7.75 (s, 1H), 6.95 (s, 1H), 5.16 (s, 2H).

[0118] Step 8: Synthesis of Compounds 1-11

[0119] Under the protection of nitrogen gas, a mixture of compound 1-10 (28 g, 185.28 mmol), POCl3 (298.30 g, 1.95 mol, 180.79 mL) and pyridine hydrochloride (21.41 g, 185.28 mmol) was heated to 120 ° C. and stirred for 16 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to remove excess POCl3, and the resulting solid was dissolved in ethyl acetate (500 mL), and then the solution was slowly poured into 1M NaH2PO4 aqueous solution (500 mL), the organic phase was separated, the aqueous phase was extracted with ethyl acetate (200 mL × 2), the combined organic phase was washed with saturated brine (350 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate: dichloromethane = 5: 1: 1) to obtain compound 1-11. 1 H NMR(400MHz, CDCl3)δ 8.45 (s, 1H), 8.06 (s, 1H), 6.94 (s, 1H).

[0120] Step 9: Synthesis of Compounds 1-12

[0121] Under the protection of nitrogen gas, dioxane (20 mL) and water (4 mL) were added to a mixture of compound 1-11 (1 g, 5.32 mmol), compound 1-6 (2.06 g, 5.85 mmol), bis(tert-butylphosphine)palladium (271.82 mg, 531.88 μmol) and K3PO4 (3.39 g, 15.96 mmol), and the resulting mixture was vacuumed and filled with nitrogen three times, and then stirred at 25 ° C for 16 hours. After the reaction was completed, the reaction solution was diluted with water (200 mL), the aqueous phase was extracted with ethyl acetate (80 mL × 2), and the combined organic phase was washed with saturated saline (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 5: 1 to 1: 2) to obtain compound 1-12. MS ESI calculated value: C 19 H 16 ClN7[M + H] + 378, Actual value: 378.

[0122] Step 10: Synthesis of Compounds 1 and 2

[0123] Under the protection of nitrogen gas, dioxane (8 mL) and water (2 mL) were added to a mixture of compound 1-12 (0.3 g, 794.01 μmol), compound 1-13 (247.81 mg, 1.19 mmol), Xphos-Pd-G2 (62.47 mg, 79.40 μmol) and Na2CO3 (252.47 mg, 2.38 mmol), and the resulting mixture was reduced in vacuum and filled with nitrogen three times, then heated to 100 ° C and stirred for 16 hours. After the reaction was completed, the reaction solution was diluted with water (60 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 2), the combined organic phase was washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 5: 1 to 1: 5) to obtain compound 1-14. Compounds 1-14 were separated by chiral separation (chiral column model: DAICEL CHIRALPAK IG (250 mm × 30 mm × 10 μm); mobile phase: A: CO2, B: 0.05% diethylamine / isopropanol, isopropanol (0.05% diethylamine) and supercritical fluid CO2 55%-55%, flow rate: 3 mL / min) to obtain compounds 1 and 2, with retention times of 1.086 min and 1.241 min, respectively (analysis method: column type: Chiralpak AD-3 50 × 4.6 mm ID, 3 μm; mobile phase: A: CO2, B: 0.05% diethylamine / isopropyl; gradient: B% = 40%; flow rate: 3 mL / min; column temperature: 35 °C). Compound 1 1 H NMR(400MHz, CDCl3)δ 8.48 (s, 1 H), 8.30 (d, J = 4.0 Hz, 2 H), 8.05 (d, J = 2.4 Hz, 1 H), 7.95 (s, 2 H), 6.93 (d, J =1.6 Hz, 1 H), 4.01 (s, 3 MS ESI calculation: C 23 H 21N9[M + H] + 424, Measured value: 424. Compound 2 1 H NMR(400MHz , CDCl3)δ 8.48 (s, 1 H), 8.30 (d, J = 4.0 Hz, 2 H), 8.05 (d, J = 2.4 Hz, 1 H), 7.95 (s, 2 H), 6.93 (d, J =1.6 Hz, 1 H), 4.01 (s, 3 MS ESI calculation: C 23 H 21 N9[M + H] + 424, Actual value: 424.

[0124] The absolute configuration of compound 1 was determined by single crystal X-ray diffraction analysis:

[0125] The crystals of compound 1 were obtained by incubating compound 1 obtained in the above Example under methanol conditions at room temperature for 5 days by the solvent evaporation method. The crystals belong to the monoclinic system, the space group is P21, and the unit cell parameters are: a = 16.4650(3) Å, b = 6.85270(10) Å, c = 19.4487(4), α = γ = 90. o , β=102.6250(10) o , volume V = 2141.33(7) Å 3 It was.

[0126] The conformational ellipsoid diagram, the unit cell packing diagram in the b-axis direction, and the absolute configuration diagram of the compound 1 are as shown in Figures 1, 2, and 3. The crystal structure data and parameters of compound 1 are as shown in Tables 1, 2, 3, 4, 5, and 6.

[0127] [Table 1]

[0128] Table 2: Atomic coordinates of the crystals (×10 4 ) and the equivalent isotropic shift parameter (Å2 ×10 3 )

[0129] [Table 2-1]

[0130] [Table 2-2]

[0131] Table 3: Bond lengths (Å) and bond angles (°) of bonded atoms

[0132] [Table 3-1]

[0133] [Table 3-2]

[0134] [Table 3-3]

[0135] Table 4: Interatomic dihedral angle values ​​(°)

[0136] [Table 4-1]

[0137] [Table 4-2]

[0138] Table 5: List of hydrogen bonds

[0139] [Table 5-1]

[0140] [Table 5-2]

[0141] Table 6: Dihedral angles

[0142] [Table 6-1]

[0143] [Table 6-2]

[0144] [Table 6-3]

[0145] Example 3

[0146] [ka]

[0147] Synthesis scheme:

[0148] [ka]

[0149] Step 1: Synthesis of compound 3-2

[0150] Compound 3-1 (1.03 g, 6.81 mmol) was dissolved in THF (25 mL) and added dropwise with lithium borohydride in tetrahydrofuran (2 M, 3.41 mL) at 0° C., then stirred at 15° C. for 16 h. The reaction mixture was quenched by adding 10 mL of 1 M hydrochloric acid, tetrahydrofuran was removed under reduced pressure, the residue was diluted with 30 mL of H2O, extracted with 40 mL of ethyl acetate (20 mL×2), the combined organic layers were washed with 20 mL of brine (20 mL), dried, filtered, concentrated under reduced pressure, and purified by column chromatography (petroleum ether:ethyl acetate=2:1) ​​to give compound 3-2. 1 HNMR (400 MHz, CDCl3) δ 3.60 (s, 2H), 2.20 (s, 6H).

[0151] Step 2: Synthesis of compound 3-3

[0152] A 50 mL round bottom flask was charged with 10 mL of DCM and oxalyl chloride (896.66 mg, 7.06 mmol, 618.39 μL) and cooled to −65° C. Dimethyl sulfoxide (1.10 g, 14.13 mmol, 1.10 mL) was added dropwise at −65° C. within 10 min, stirred for 10 min, and compound 3-2 (580 mg, 4.71 mmol) was dissolved in 5 mL of dichloromethane and added dropwise to the reaction system at −65° C. The reaction mixture was stirred at the same temperature for 1 h, and TEA (2.38 g, 23.55 mmol, 3.28 mL) was added at −65° C. within 10 min. The reaction mixture was diluted with water and extracted with dichloromethane, the organic layers were combined, washed with 1 M aqueous hydrochloric acid and brine, dried and concentrated to give compound 3-3. 1 HNMR (400MHz, CDCl3) δ 9.52 (s, 1H), 2.52 (s, 6H).

[0153] Step 3: Synthesis of Compound 3-4

[0154] Diethyl cyanomethylphosphonate (754.56 mg, 4.26 mmol, 685.96 μL), lithium bromide (462.44 mg, 5.32 mmol, 133.65 μL) and triethylamine (718.39 mg, 7.10 mmol, 988.16 μL) were added to THF (6 mL), compound 3-3 (430 mg, 3.55 mmol) was dissolved in THF (4 mL), and the latter was added to the former reaction system and stirred at 15 ° C for 16 h. The mixture was diluted with water and extracted with ethyl acetate (20 mL × 1), and the combined organic layer was washed with 20 mL of brine (20 mL × 1), dried, concentrated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to give compound 3-4. 1 HNMR (400 MHz, CDCl3) δ 6.64 (d, J = 16.4 Hz, 1H), 5.32 (d, J = 16.4 Hz, 1H), 2.40 (s, 6H).

[0155] Step 4: Synthesis of compounds 3-5

[0156] Compound 1-11 (5.5 g, 29.25 mmol), pyrazole-4-boronic acid pinacol ester (6.81 g, 35.10 mmol), Pd(PPh3)4 (3.38 g, 2.93 mmol), sodium carbonate (6.20 g, 58.51 mmol) were added to dioxane (60 mL) and water (15 mL) and stirred at 50 °C for 16 h under nitrogen gas atmosphere. Diluted with water, extracted the mother liquor with EA 120 mL (60 mL × 2), combined organic layer was washed with 60 mL of brine (60 mL × 1), dried, concentrated and purified by column chromatography (petroleum ether: ethyl acetate = 0: 1) to give compound 3-5. 1 HNMR (400 MHz, DMSO-d6) δ 13.55 (brs, 1H), 8.96 (s, 1H), 8.73 (s, 1H), 8.33 (s, 1H), 8.25 (s, 1H), 7.50 (dd, J = 1.2, 2.4 Hz, 1H).

[0157] Step 5: Synthesis of Compounds 3-6

[0158] 3-5 (150 mg, 682.97 μmol) was dissolved in acetonitrile (4 mL), DBU (103.97 mg, 682.97 μmol) and 3-4 (108.31 mg, 751.27 μmol) were added, and the mixture was stirred for 1 hour at 15° C. The mixture was concentrated under reduced pressure and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 3-6. 1 HNMR (400 MHz, CDCl3) δ 8.39 (d, J = 0.8 Hz, 1H), 8.27 (s, 1H), 8.22 (s, 1H), 8.09 (d, J = 2.4 Hz, 1H), 6.98 (dd, J = 0.8, 2.4 Hz, 1H), 4.63 (dd, J = 6.4, 8.0 Hz, 1H), 3.08-3.20 (m, 1H), 2.93-3.03 (m, 1H), 2.38-2.24 (m, 6H).

[0159] Step 6: Synthesis of the trifluoroacetate salt of compound 3

[0160] Compound 3-6 (180 mg, 494.77 μmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (113.24 mg, 544.25 μmol), Xphos-Pd-G2 (77.86 mg, 98.95 μmol) and sodium carbonate (157.32 mg, 1.48 mmol) were added to water (1 mL) and dioxane (4 mL) and stirred at 100° C. for 16 hours under nitrogen gas. The reaction mixture was concentrated under reduced pressure to dryness, diluted with 20 mL of water, extracted with ethyl acetate (15 mL × 2), and the combined organic layers were washed with brine (20 mL), dried, concentrated, and purified by column chromatography (petroleum ether: ethyl acetate = 0: 1) and high performance liquid chromatography (column type: Phenomenex Synergi C18 150 mm × 25 mm × 10 μm; mobile phase: [water (0.1% trifluoroacetic acid)-acetonitrile]; B (acetonitrile) %: 38% ~ 58%, 10 min) to obtain compound 3. 1HNMR (400 MHz, DMSO-d6) δ 8.86 (s, 1 H), 8.84 (s, 1H), 8.47 (s, 1H), 8.24 (d, J = 2.4 Hz, 1H), 7.82 (d, J = 2.4 Hz, 1H), 7.38 (d, J = 1.6 Hz, 1H), 6.94 (d, J = 2.0 Hz, 1H), 4.99 (dd, J = 5.6, 9.2 Hz, 1H), 3.94 (s, 3H), 3.39 - 3.20 (m, 2H), 2.28 - 2.12 (m, 6H). MS ESI calculated value: C 22 H 19 N9[M + H] + 410, found: 410.

[0161] Examples 4 and 5

[0162]

Chem.

[0163] Synthesis scheme:

[0164]

Chem.

[0165] Step 1: Synthesis of Compound 4-2

[0166] Under the protection of nitrogen gas at 25 ° C, dioxane (8 mL) and water (2 mL) were added to a mixture of compound 1-12 (0.36 g, 952.81 μmol), compound 4-1 (218.07 mg, 1.05 mmol), BrettPhos Pd G3 (149.93 mg, 190.56 μmol) and Na2CO3 (302.96 mg, 2.86 mmol), and the resulting mixture was reduced in vacuum and filled with nitrogen three times, then heated to 100 ° C and stirred for 16 hours. After the reaction was completed, the reaction solution was diluted with water (5 mL), and the aqueous phase was extracted with ethyl acetate (20 mL × 3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3: 1 to 2: 1) to obtain compound 4-2. MS ESI calculated value: C 23 H 21 N9[M + H] + 424, Actual value: 424.

[0167] Step 2: Synthesis of Compound 4 and Compound 5

[0168] Compound 4-2 was separated by chiral separation (chiral column model: DAICEL CHIRALPAK AD (250 mm × 30 mm × 10 μm); mobile phase: A: carbon dioxide, B: 0.1% ammonia / methanol, 0.1% ammonia / methanol and supercritical fluid carbon dioxide are 60% to 60%, flow rate: 70 mL / min), and then compound 4 and compound 5 (analysis method: column type Amycoat 50 × 4.6 mm ID, 3 μm; mobile phase: A: CO2, B: methanol + acetonitrile (0.05% diethylamine); gradient: 60% methanol + acetonitrile (0.05% diethylamine); flow rate: 3 mL / min; column temperature: 35 °C) were obtained. The retention times were 1.045 min and 1.375 min, respectively.

[0169] Compound 4: 11H NMR (400 MHz, CDCl3) δ 8.89 (s, 1H), 8.36 (s, 1H), 8.31 (s, 1H), 8.09 (d, J = 2.4 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 6.96 (d, J = 1.8 Hz, 1H), 6.88 (d, J = 2.2 Hz, 1H), 4.01 (s, 3H), 3.07 - 3.15 (m, 1H), 2.98 - 3.07 (m, 4H), 2.79 (dt, J = 2.3, 13.8 Hz, 2H), 2.61 - 2.72 (m, 2H), 2.43 - 2.55 (m, 2H). MS ESI calculated value: C 23 H 21 N9[M + H] + 424, found: 424.

[0170] Compound 5: 1 1H NMR (400 MHz, CDCl3) δ 8.90 (s, 1H), 8.36 (s, 1H), 8.31 (s, 1H), 8.09 (d, J = 2.3 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 6.96 (d, J = 1.6 Hz, 1H), 6.89 (d, J = 2.2 Hz, 1H), 4.02 (s, 3H), 3.08 - 3.17 (m, 1H), 2.99 - 3.07 (m, 4H), 2.79 (dt, J = 2.2, 13.7 Hz, 2H), 2.60 - 2.72 (m, 2H), 2.44 - 2.56 (m, 2H). MS ESI calculated value: C 23 H 21 N9[M + H] + 424, found: 424.

[0171] Example 6

[0172]

Chem.

[0173] Synthesis scheme:

[0174] [ka]

[0175] Step 1: Synthesis of compound 6-1

[0176] Compound 3-5 (1.19 g, 5.42 mmol) was dissolved in anhydrous THF (18 mL), sodium hydride (325.06 mg, 8.13 mmol, 60% purity) was added in batches at 0 °C, and the mixture was stirred at 0 °C for 0.5 h. 2-(trimethylsilyl)ethoxymethyl chloride (993.66 mg, 5.96 mmol) was added dropwise at 0 °C, and the mixture was warmed to 20 °C and stirred for 0.5 h. The reaction mixture was diluted with 60 mL of water and extracted with ethyl acetate (30 mL × 2), and the combined organic layers were washed with brine (30 mL × 1), dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (petroleum ether: ethyl acetate = 5: 1) to give compound 6-1. 1 H NMR (400 MHz, CDCl3) δ 8.38 (d, J = 0.8 Hz, 1H), 8.36 (s, 1H), 8.27 (s, 1H), 8.05-8.11 (d, J =2.4 Hz, 1H), 7.01 (dd, J = 0.8, 2.4 Hz, 1H), 5.54 (s, 2H), 3.64 (d, J = 6.8 Hz, 2H), 0.96 (s, 2H), 0.03 (s, 9H).

[0177] Step 2: Synthesis of compound 6-2

[0178] Compound 6-1 (1.65 g, 4.72 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.08 g, 5.19 mmol), X-Phos Pd G2 (742.08 mg, 943.15 μmol) and sodium carbonate (1.50 g, 14.15 mmol) were added to HO (6 mL) and dioxane (25 mL) and reacted at 100 °C for 16 hours under nitrogen gas atmosphere. The reaction solution was diluted with 80 mL of water, filtered, the mother liquor was extracted with ethyl acetate (50 mL × 2), the organic layers were combined, washed with brine (60 mL × 1), dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (petroleum ether: ethyl acetate = 1:2) to obtain compound 6-2. 1 H NMR (400 MHz, CDCl3) δ 8.91 (d, J = 0.8 Hz, 1H), 8.38 (s, 1H), 8.32 (s, 1H), 8.04-8.13 (m, 1H), 7.45 (d, J = 2.4 Hz, 1H), 6.96 (dd, J = 0.8, 2.4 Hz, 1H), 6.91 (d, J = 2.4 Hz, 1H), 5.55 (s, 2H), 4.01 (s, 3H), 3.63-3.70 (m, 2H), 0.93-1.00 (m, 2H), 0.00 (s, 9H).

[0179] Step 3: Synthesis of compound 6-3

[0180] Compound 6-2 (1.76 g, 4.45 mmol) was dissolved in hydrochloric acid methanol (4 M, 25 mL), reacted at 50° C. for 16 hours, concentrated under reduced pressure, diluted with methyl tert-butyl ether (20 mL), stirred at 15° C. for 30 minutes, filtered, and dried under vacuum to give compound 6-3. MS ESI calculated value: C 13 H 11 N7[M + H] + 266, Actual value: 266.

[0181] Step 4: Synthesis of compound 6-5

[0182] Compound 6-4 (0.5 g, 2.37 mmol) was dissolved in tetrahydrofuran (5 mL), and a solution of diethyl cyanomethylphosphonate (503.09 mg, 2.84 mmol), lithium bromide (308.31 mg, 3.55 mmol) and triethylamine (478.99 mg, 4.73 mmol, 658.86 μL) in tetrahydrofuran (10 mL) was added and reacted at 15 ° C for 2 hours. The reaction solution was diluted with 50 mL of water, extracted with ethyl acetate (30 mL × 2), and the organic layers were combined and washed with brine (30 mL × 1), dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 6-5. 1 H NMR (400 MHz, CDCl3) δ 5.13-5.27 (m, 1H), 3.92-4.03 (m, 4H), 3.10-3.18 (m, 2H), 3.02-3.07 (m, 2H), 1.43 (s, 9H).

[0183] Step 5: Synthesis of compound 6-6

[0184] Compound 6-3 (0.3 g, 994.25 μmol) was dissolved in acetonitrile (6 mL), and 1,8-diazabicyclo[5.4.0]undecane-7-ene (454.10 mg, 2.98 mmol, 449.60 μL) and compound 6-5 (256.24 mg, 1.09 mmol) were added and reacted for 16 hours at 15° C. The mixture was concentrated under reduced pressure to dryness, and purified by column chromatography (petroleum ether / ethyl acetate=1 / 3) to obtain compound 6-6. 1H NMR (400 MHz, CDCl3) δ 8.88 (d, J = 0.8 Hz, 1H), 8.36 (s, 1H), 8.30 (s, 1H), 8.08 (d, J = 2.4 Hz, 1H), 7.45 (d, J = 2.4 Hz, 1H), 6.95 (dd, J = 0.8, 2.4 Hz, 1H), 6.88 (d, J = 2.4 Hz, 1H), 4.13 (s, 2H), 4.00 (s, 3H), 3.94 (s, 2H), 3.11 (s, 1H), 3.08 (s, 1H), 3.02 (s, 2H), 2.86 (s, 1H), 2.83 (s, 1H), 1.44 (s, 9H).

[0185] Step 6: Synthesis of Compounds 6-7

[0186] Compound 6-6 was dissolved in dichloromethane (1 mL), trifluoroacetic acid (308.00 mg, 2.70 mmol, 0.2 mL) was added, and the mixture was reacted at 15° C. for 0.5 hours. The pH of the reaction solution was adjusted to 7 with 25% ammonia, concentrated under reduced pressure, dried, and purified by high performance liquid chromatography (column: Waters Xbridge 150×25 mm×5 μm; mobile phase: [water (10 mM sodium bicarbonate)-acetonitrile]; B (acetonitrile)%: 8% to 38%, 10 min) to obtain compound 6-7. 1 H NMR (400 MHz, CD3OD) δ 8.82 (s, 1H), 8.72 (s, 1H), 8.41 (s, 1H), 8.10 (d, J = 1.6 Hz, 1H), 7.64 (d, J = 1.6 Hz, 1H), 7.23 (d, J = 2.4 Hz, 1H), 6.90 (d, J = 2.4 Hz, 1H), 4.02 (s, 2H), 3.97 (s, 3H), 3.86 (s, 2H), 3.24 (s, 2H), 3.06-3.20 (m, 2H), 2.73-2.96 (m, 2H). MS ESI calculated value:C 21 H 21 N9[M + H] + 400, Actual value: 400.

[0187] Step 7: Synthesis of compound 6

[0188] Compound 6-7 (70 mg, 140.12 μmol) was dissolved in dichloromethane (1 mL), trifluoroacetic acid (299.44 mg, 2.63 mmol, 194.44 μL) was added, and the mixture was stirred for 0.5 hours at 15° C. Next, triethylamine (318.06 mg, 3.14 mmol, 437.50 μL) and bromoacetonitrile (25.21 mg, 210.18 μmol) were added, and the reaction solution was stirred for 16 hours at 15° C. The residue was concentrated under reduced pressure to dryness and purified twice by high performance liquid chromatography, the first time (column type: Xtimate C18 150 × 40 mm × 10 μm; mobile phase: [water (0.05% ammonia v / v)-ACN]; B(ACN)%: 20%-50%, 10 min) and the second time (column type: WatersXbridge 150 × 25 mm × 5 μm; mobile phase: [water (10 mM sodium bicarbonate)-ACN]; B(ACN)%: 14%-44%, 10 min), to give compound 6. 1 H NMR (400 MHz, CD3OD) δ 8.85 (s, 1H), 8.75 (s, 1H), 8.43 (s, 1H), 8.07-8.18 (m, 1H), 7.67 (d, J = 2.4 Hz, 1H), 7.21-7.33 (m, 1H), 6.99 - 6.86 (m, 1H), 3.99 (s, 3H), 3.58 (s, 2H), 3.56 (s, 2H), 3.41 (s, 2H), 3.23 (s, 2H), 3.13 (s, 1H), 3.10 (s, 1H), 2.83 (s, 1H), 2.80 (s, 1H). MS ESI calculation value:C 23 H 22 N 10 [M + H] + 439, Actual value: 439.

[0189] Example 7

[0190] [ka]

[0191] Synthesis scheme:

[0192] [ka]

[0193] Synthesis of compound 7

[0194] Compound 6-6 (100 mg, 200.17 μmol) was dissolved in dichloromethane (1 mL), trifluoroacetic acid (308.00 mg, 2.70 mmol, 0.2 mL) was added, and the mixture was stirred at 15° C. for 0.5 hours. Next, triethylamine (324.09 mg, 3.20 mmol, 445.79 μL) was added, the mixture was cooled to 0° C., bromonitrile (0.32 g, 3.02 mmol) was added, and the mixture was stirred at 0° C. for 0.5 hours. The reaction solution was diluted with 30 mL of water and extracted with 40 mL of dichloromethane (20 mL × 2), and the combined organic layers were washed with 20 mL of brine, dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by high performance liquid chromatography (column: Waters Xbridge 150 × 25 mm × 5 μm; mobile phase: [water (10 mM sodium bicarbonate)-acetonitrile]; B (ACN) %: 14%-44%, 10 min) to obtain compound 7. 1 HNMR (400 MHz, CD3OD) δ 8.88 (d, J = 1.2 Hz, 1H), 8.76 (s, 1H), 8.45 (s, 1H), 8.14 (d, J = 2.4 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.28 (dd, J = 1.0, 2.4 Hz, 1H), 6.94 (d, J = 2.4 Hz, 1H), 4.37 (s, 2H), 4.20 (s, 2H), 4.00 (s, 3H), 3.23 (s, 2H), 3.15-3.22 (m, 2H), 2.85-2.95 (m, 2H). MS ESI calculation value:C 22 H 20 N 10 [M + H]+ 425, Actual value: 425.

[0195] Example 8

[0196] [ka]

[0197] Synthesis scheme:

[0198] [ka]

[0199] Step 1: Synthesis of compound 8-2

[0200] Compound 8-1 (20 g, 237.77 mmol) and imidazole (32.37 g, 475.53 mmol) were added to anhydrous dichloromethane (300 mL), tert-butylchlorodiphenylsilane (68.62 g, 249.65 mmol, 64.13 mL) was added dropwise at 0 ° C., and the mixture was stirred at 20 ° C. for 16 hours under the protection of nitrogen gas. After the reaction was completed, water (200 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (100 mL × 3), and the combined extraction solution was washed with water (200 mL × 2), brine (200 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 1: 0) to obtain compound 8-2. 1 H NMR (400 MHz, CDCl3) δ 7.65-7.72 (m, 4H), 7.37-7.46 (m, 6H), 5.63 (s, 2H), 4.52-4.62 (m, 1H), 2.36-2.50 (m, 4H), 1.07 (s, 9H).

[0201] Step 2: Synthesis of compound 8-4

[0202] Compound 8-2 (66 g, 204.64 mmol) and rhodium acetate (904.48 mg, 4.09 mmol) were added to anhydrous dichloromethane (600 mL), and a solution of compound 8-3 (28.02 g, 245.57 mmol, 25.71 mL) in dichloromethane (200 mL) was added dropwise for about 5 hours. The mixture was stirred at 20 ° C for 15 hours under the protection of nitrogen gas. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, the filtrate was concentrated, and the obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 1: 0 to 20: 1) to obtain compound 8-4. 1 H NMR (400 MHz, CDCl3) δ 7.60-7.71 (m, 4H), 7.34-7.47 (m, 6H), 4.19-4.59 (m, 1H), 3.84-4.18 (m, 2H), 2.12-2.49 (m, 1H), 2.00-2.07 (m, 1H), 1.77-1.98 (m, 4H), 1.17-1.55 (m, 3H), 1.09-1.15 (m, 1H), 1.02-1.08 (m, 9H).

[0203] Step 3: Synthesis of compound 8-5

[0204] Compound 8-4 (55 g, 134.60 mmol) was added to anhydrous ethanol (200 mL), and a solution of sodium hydroxide (16.15 g, 403.81 mmol) in water (50 mL) was added dropwise, followed by stirring at 20 ° C for 16 hours. After completion of the reaction, the reaction solution was concentrated to remove ethanol, adjusted to pH 3-4 with 1 M hydrochloric acid, extracted with ethyl acetate (100 mL × 2), combined the extract solution, concentrated, and the obtained crude product was added to petroleum ether (450 mL) and stirred at 20 ° C for 1 hour. The cake was obtained by filtration, and after drying, compound 8-5 was obtained. 1H NMR (400 MHz, DMSO-d6) δ 11.22-12.70 (brs, 1H), 7.52-7.60 (m, 4H), 7.39-7.49 (m, 6H), 3.87-4.33 (m, 1H), 1.92-2.00 (m, 2H), 1.62-1.83 (m, 4H), 1.04 (t, J = 2.9 Hz, 1H), 0.85-0.98 (m, 9H).

[0205] Step 4: Synthesis of compound 8-6

[0206] Compound 8-5 (30 g, 78.83 mmol) was added to N,N-dimethylformamide (100 mL), and 2-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (44.96 g, 118.25 mmol) and N,N-diisopropylethylamine (30.57 g, 236.50 mmol) were added successively at 15 ° C., and the mixture was stirred at 25 ° C. for 0.5 hours. Then, ammonium chloride (12.65 g, 236.50 mmol) was added in batches at 15 ° C., and the mixture was stirred at 25 ° C. for 1 hour. After the reaction was completed, the reaction solution was diluted with water (200 mL), extracted with ethyl acetate (300 mL × 3), and the combined extraction solution was washed with brine (500 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. Compound 8-6 was obtained. 1 H NMR (400 MHz, DMSO-d6) δ 7.55-7.62 (m, 4H), 7.41-7.51 (m, 6H), 7.21 (brs, 1H), 6.55-6.70 (m, 1H), 3.75-4.20 (m, 1H), 1.92-2.05 (m, 2H), 1.65-1.85 (m, 2H), 1.45-1.60 (m, 1H), 1.05-1.10 (m, 1H), 0.85-1.04 (m, 9H).

[0207] Step 5: Synthesis of compound 8-7

[0208] 8-6 (25.00 g, 65.86 mmol) and triethylamine (33.32 g, 329.32 mmol, 45.84 mL) were added to anhydrous dichloromethane (200 mL), trifluoroacetic anhydride (44.96 g, 118.25 mmol) was added dropwise at 0 ° C, and the mixture was stirred at 0 ° C for 1 hour. After the reaction was completed, the reaction solution was quenched by adding saturated aqueous sodium bicarbonate solution (100 mL), extracted with dichloromethane (50 mL × 3), the extracted solution was combined and washed with saturated aqueous sodium bicarbonate solution (100 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 20: 1 to 10: 1) to obtain compound 8-7. 1 H NMR (400 MHz, DMSO-d6) δ 7.54-7.60 (m, 4H), 7.39-7.49 (m, 6H), 3.92-4.06 (m, 1H), 1.95-2.10 (m, 2H), 1.80-1.85 (m, 2H), 1.70-1.82 (m, 2H), 1.39 (t, J = 3.4 Hz, 1H), 0.96 (s, 9H).

[0209] Step 6: Synthesis of compound 8-8

[0210] Compound 8-7 (22.00 g, 60.85 mmol) was added to tetrahydrofuran (200 mL), tetrabutylammonium fluoride (1 M THF solution, 91.27 mL) was added dropwise at 15 ° C, and the mixture was stirred at 25 ° C for 16 hours. After the reaction was completed, the reaction solution was quenched by adding saturated aqueous ammonium chloride solution (200 mL), extracted with ethyl acetate (200 mL × 3), the combined extract solution was washed with brine (200 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10: 1 to 1: 2) to obtain compound 8-8.

[0211] Step 7: Synthesis of compounds 8-9

[0212] Compound 8-8 (5.5 g, 44.66 mmol) was added to dichloromethane (200 mL), and Dess-Martin oxidant (28.41 g, 66.99 mmol) was added dropwise at 0 °C, and the mixture was stirred at 25 °C for 16 hours. After the reaction was completed, the reaction solution was quenched by adding saturated aqueous sodium thiosulfate solution (200 mL) and saturated aqueous sodium bicarbonate solution (200 mL), stirred at 20 °C for 10 minutes, extracted with dichloromethane (200 mL × 3), the combined extracted solution was washed with saturated aqueous sodium bicarbonate solution (100 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10: 1 to 2: 1) to obtain compound 8-9. 1 H NMR (400 MHz, CDCl3) δ 2.63-2.73 (m, 2H), 2.23-2.35 (m, 4H), 0.95-1.05 (m, 1H).

[0213] Step 8: Synthesis of Compounds 8-10

[0214] Compound 8-9 (7.72 g, 43.59 mmol), LiBr (5.16 g, 59.44 mmol) and TEA (8.02 g, 79.25 mmol, 11.03 mL) were added to anhydrous tetrahydrofuran (50 mL), and a solution of diethyl cyanomethylphosphonate (4.80 g, 39.62 mmol) in anhydrous tetrahydrofuran (50 mL) was added dropwise at 25 ° C. and stirred at 25 ° C. for 16 hours. After the reaction was completed, water (100 mL) was added to the reaction solution, extracted with ethyl acetate (100 mL × 3), the extraction solution was combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10: 1 to 3: 1) to obtain compound 8-10. 1 H NMR (400 MHz, CDCl3) δ 5.33 (s, 1H), 2.94-3.03 (m, 1H), 2.84-2.93 (m, 2H), 2.60-2.75 (m, 1H), 2.10-2.24 (m, 2H), 0.82-0.93 (m, 1H).

[0215] Step 9: Synthesis of compound 8

[0216] Compound 8-10 (0.60 g, 1.99 mmol) and potassium carbonate (824.47 mg, 5.95 mmol) were added to water (12 mL), and a solution of compound 6-3 (430.03 mg, 2.98 mmol) in dioxane (8 mL) was added dropwise at 20 ° C., and the mixture was stirred at 80 ° C. for 4 hours. After the reaction was completed, water (50 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL × 3), and the extraction solution was combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The obtained crude product was purified by preparative thin layer chromatography (petroleum ether: ethyl acetate = 0: 1) and preparative high performance liquid chromatography (column model: Phenomenex Gemini-NX C18 75 × 30 mm × 3 μm; mobile phase: [water (0.1% TFA)-ACN]; B (ACN) %: 25% ~ 55%, 7 min) to obtain compound 8. 1 H NMR (400 MHz, CD3OD) δ 7.28-7.33 (m, 1H), 7.04-7.18 (m, 1H), 6.80-6.89 (m, 1H), 6.53-6.60 (m, 1H), 6.09-6.15 (m, 1H), 5.64-5.72 (m, 1H), 5.35-5.40 (m, 1H), 4.01-4.08 (m, 1H), 3.18-3.26 (m, 2H), 2.43 (s, 3H), 1.75-1.80 (m, 1H), 1.35-1.65 (m, 3H), 0.66-1.17 (m, 2H).MS ESI calculation value:C 22 H 19 N9[M + H] + 410, Actual value: 410.

[0217] Example 9

[0218] [ka]

[0219] Synthesis scheme:

[0220] [ka]

[0221] Step 1: Synthesis of compound 9-2

[0222] Under nitrogen gas atmosphere, potassium tert-butoxide (1M, 4.60mL) was added to tetrahydrofuran (5mL), and diethyl cyanomethylphosphonate (814.22mg, 4.60mmol, 740.20μL) was added to the above solution at 0℃ and stirred at 0℃ for 20min. 9-1 (1g, 4.18mmol) was dissolved in tetrahydrofuran (5mL) and added to the above solution and stirred at 20℃ for 2h. The reaction mixture was poured into water (100mL), extracted with ethyl acetate (60mL×3), washed with brine (80mL), dried over sodium sulfate, concentrated to dryness and purified by silica gel column (petroleum ether:ethyl acetate=5:1) to give compound 9-2. 1 H NMR (400 MHz, CDCl3) δ 5.20-5.30 (m, 1 H), 3.20-3.45 (m, 4 H), 2.72 (d, J = 1.6 Hz, 2 H), 2.62 (d, J = 1.6 Hz, 2 H), 1.50-1.65 (m, 4 H), 1.46 (s, 9 H).

[0223] Step 2: Synthesis of compound 9-3

[0224] 6-3 (0.3 g, 994.25 μmol) was dissolved in acetonitrile (4 mL), 1,8-diazabicyclo[5.4.0]undecane-7-ene (454.10 mg, 2.98 mmol, 449.60 μL) and compound 9-2 (286.92 mg, 1.09 mmol) were added, and the mixture was stirred at 15 °C for 16 hours. The mixture was concentrated under reduced pressure and purified by silica gel column (petroleum ether: ethyl acetate = 10: 1 to 1: 3) to obtain compound 9-3. MS ESI calculated value: C 28 H 33 NO2[M+H] + 528, Actual value: 528.

[0225] Step 3: Synthesis of compound 9

[0226] Compound 9-3 (70 mg, 125.51 μmol) was dissolved in dichloromethane (1 mL), trifluoroacetic acid (291.37 mg, 2.56 mmol, 189.20 μL) was added, and stirring was continued for 0.5 h at 15° C. Then, triethylamine (317.50 mg, 3.14 mmol, 436.73 μL) was added, the mixture was cooled to 0° C., bromonitrile (15.95 mg, 150.61 μmol) was added, and stirring was continued for 0.5 h at 0° C. 30 mL of water was added, and extracted with 40 mL of dichloromethane (20 mL × 2), the organic layers were combined, washed with 20 mL of brine, dried over sodium sulfate, concentrated to dryness, and purified by high performance liquid chromatography (column model: WatersXbridge 150 × 25 mm × 5 μm; mobile phase: [water (0.1% ammonium bicarbonate)-acetonitrile]; B (acetonitrile)%: 16%-46%, 10 min) to obtain compound 9. 1 H NMR(400 MHz, CD3OD) δ 8.88 (d, J = 1.2 Hz, 1H), 8.84 (s, 1H), 8.46 (s, 1H), 8.14 (d, J = 2.4 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.28 (dd, J = 0.8, 2.4 Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 3.92 (s, 3H), 3.27 (s, 2H), 3.22-3.26 (m, 2H), 3.16-3.21 (m, 2H), 2.92 (d, J = 14.4 Hz, 2H), 2.53 (d, J = 14.4 Hz, 2H), 1.82-1.92 (m, 2H), 1.56-1.72 (m, 2H). MS ESI calculated value: C 24 H 24 N 10 [M + H] + 453, Actual value: 453.

[0227] Examples 10 and 11

[0228] [ka]

[0229] Synthesis scheme:

[0230] [ka]

[0231] Step 1: Synthesis of compound 10-1

[0232] 1,8-diazabicyclo[5.4.0]undecane-7-ene (302.72 mg, 1.99 mmol, 299.73 μL) and 10-4 (181.05 mg, 729.12 μmol) were added to 6-3 (0.2 g, 662.84 μmol) in acetonitrile (3 mL), and the mixture was reacted at 25° C. for 16 hours. The mixture was concentrated under reduced pressure and purified by a silica gel chromatography column (petroleum ether: ethyl acetate = 2:1) to obtain compound 10-1. MS ESI calculated value: C 27 H 31 NO2[M + H] + 514, Actual value: 514.

[0233] Step 2: Synthesis of compound 10-2

[0234] Compound 10-1 (330 mg, 642.53 μmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (1.85 g, 16.21 mmol, 1.2 mL) was added, and the mixture was reacted at 25° C. for 1 hour. The mixture was concentrated under reduced pressure and dried to obtain compound 10-2. MS ESI calculated value: C 22 H 23 N9[M + H] + 414, Actual value: 414.

[0235] Step 3: Synthesis of compound 10-4

[0236] A solution of compound 10-3 (1 g, 4.44 mmol) in tetrahydrofuran (5 mL) was added with a solution of diethyl cyanomethylphosphonate (943.56 mg, 5.33 mmol, 857.78 μL), anhydrous lithium bromide (578.27 mg, 6.66 mmol) and triethylamine (898.33 mg, 8.88 mmol) in tetrahydrofuran (5 mL), and reacted for 16 hours at 25 ° C. The reaction solution was diluted with 100 mL of water, extracted with 120 mL of ethyl acetate (60 mL × 2), and the combined organic layer was washed with 80 mL of brine, dried over sodium sulfate, concentrated under reduced pressure, and purified by silica gel chromatography column (petroleum ether: ethyl acetate = 3: 1) to obtain compound 10-4. 1 HNMR(400MHz, CDCl3) δ 5.17-5.31 (m, 1H), 3.32-3.49 (m, 4H), 2.73-3.02 (m, 4H), 1.86-1.99 (m, 2H), 1.46 (s, 9H).

[0237] Step 4: Synthesis of Compounds 10 and 11

[0238] Compound 10-2 (0.34 g, 644.55 μmol) was dissolved in 8 mL of dichloromethane, and bromonitrile (136.54 mg, 1.29 mmol, 94.82 μL) and triethylamine (326.11 mg, 3.22 mmol, 448.57 μL) were added thereto, followed by reaction at 25° C. for 2 hours. Diluted with 100 mL of water, extracted with dichloromethane (50 mL x 2), combined organic layers were washed with 50 mL of brine, dried over sodium sulfate, purified by silica gel chromatography column (petroleum ether / ethyl acetate = 1 / 2) and separated by chiral separation (chiral column model: DAICEL CHIRALPAK AD (250 mm x 30 mm x 10 μm); mobile phase: [0.1% ammonia / ethanol]; B (ethanol) %: 60%-60%, 4.1 min) to obtain compound 10 and compound 11 (analysis method: column type Chiralpak AD-3 50 x 4.6 mm ID, 3 μm; mobile phase: A: CO2, B: ethanol (0.05% diethylamine); gradient: B phase 40%; flow rate: 3 mL / min; column temperature: 35 °C). The retention times were 1.288 min and 2.367 min, respectively. Compound 10 1 H NMR (400 MHz, DMSO-d6) δ 8.87 (d, J = 2.0 Hz, 2H) , 8.49 (s, 1H), 8.25 (d, J = 2.4 Hz, 1H), 7.83 (d, J = 2.0 Hz, 1H), 7.48 (d, J = 1.6 Hz, 1H), 6.98 (d, J = 2.0 Hz, 1H), 3.94 (s, 3H), 3.53 (s, 2H), 3.46 (s, 2H), 3.35-3.38 (m, 2H), 2.97 (d, J = 14 Hz, 2H), 2.63 (d, J = 14 Hz, 2H), 1.83 (t, J = 7.2 Hz, 2H).MS ESI calculation value:C 23 H 22 N 10 [M + H] + 439, Measured value: 439. Compound 11 1HNMR (400 MHz, DMSO-d6) δ 8.86 (d, J = 3.6 Hz, 2H), 8.49 (s, 1H), 8.25 (d, J = 2.4 Hz, 1H), 7.83 (d, J = 2.0 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 6.99 (d, J = 2.4 Hz, 1H), 3.94 (s, 3H), 3.48 (s, 2H), 3.42 (t, J = 6.8 Hz, 2H), 3.31 (s, 2H), 3.01 (d, J = 13.6 Hz, 2H), 2.57 (d, J = 13.6 Hz, 2H), 2.09 (t, J = 6.8 Hz, 2H). MS ESI calculated value: C 23 H 22 N 10 [M + H] + 439, found: 439.

[0239] Example 12 or 13

[0240]

Chemical Structure

[0241] Synthesis Scheme:

[0242]

Chemical Structure

[0243] Step 1: Synthesis of Compound 12-2

[0244] Under the protection of nitrogen gas at -10°C, n-butyllithium (2.5M, 17.93mL) was slowly added dropwise to a suspension of methyltriphenylphosphine bromide (17.15g, 48.02mmol) in tetrahydrofuran (50mL), and after completion of the addition, stirring was continued for 1 hour at the same temperature. Compound 12-1 (5g, 32.01mmol) was added to the above suspension, and the reaction system was warmed to 20°C and stirred for 3 hours. After completion of the reaction, acetone (100mL) was added to quench the reaction system, and the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate=5:1) to obtain compound 12-2. 1 HNMR(400MHz,CDCl3)δ 4.65 (s, 2 H), 3.67 (s, 3 H), 2.40-2.55 (m, 1 H), 2.25-2.39 (m, 2 H), 1.90-2.10 (m, 4 H), 1.45-1,65 (m, 4 H).

[0245] Step 2: Synthesis of compound 12-3

[0246] Under the protection of nitrogen gas at 0°C, 2,2,2-trichloroacetyl chloride (2.83g, 15.56mmol, 1.74mL) was slowly added dropwise to a suspension of compound 12-2 (2g, 12.97mmol) and zinc-copper reagent (5.02g, 38.91mmol) in diethyl ether (30mL). During the addition process, the reaction was very exothermic and the temperature rose rapidly, after which the addition was started again while strictly controlling the internal temperature to about 0°C. After the addition was completed, the reaction system was slowly warmed to 20°C and then stirred at that temperature for 1 hour. The reaction system was then cooled to -5°C, methanol (10mL) was added, and zinc powder (2.54g, 38.91mmol) was added in batches within 1 hour. After the addition was completed, the mixture was slowly warmed to 20°C, then diatomaceous earth was added, the resulting mixture was filtered through diatomaceous earth, the cake was rinsed with ethyl acetate (50 mL × 3), the resulting filtrate was washed with saturated brine (80 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 0: 1 to 3: 1) to obtain compound 12-3. 1HNMR(400MHz,CDCl3)δ 3.61 (s, 3 H), 2.69 (s, 4 H), 2.20-2.30 (m, 1 H), 1.80-1.95 (m, 2 H), 1.65-1.75 (m, 2 H), 1.40-1.60 (m, 4 H).

[0247] Step 3: Synthesis of compound 12-4

[0248] A solution of compound 12-3 (0.4 g, 2.04 mmol) and sodium hydroxide (163.05 mg, 4.08 mmol) in water (10 mL) and methanol (50 mL) was heated to 65° C. and stirred for 1 h. After completion of the reaction, the reaction mass was cooled to 0° C., the pH was adjusted to 6 with 2 M hydrochloric acid, extracted with ethyl acetate (10 mL×3), the combined extract solution was washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give compound 12-4. 1 H NMR(400MHz, DMSO-D6)δ 2.72 (s, 4 H), 2.05-2.15 (m, 1 H), 1.15-1.90 (m, 8 H).

[0249] Step 4: Synthesis of compound 12-5

[0250] Under the protection of nitrogen gas at 0°C, oxalyl chloride (313.46mg, 2.47mmol, 216.18μL) was added dropwise to a solution of compound 12-4 (0.3g, 1.65mmol) in tetrahydrofuran (40.00mL) and DMF (0.05mL), and after the completion of the addition, stirring was continued at 0°C for 1 hour. The mixture was concentrated under reduced pressure, and the residue was dissolved again in a dichloromethane (10mL) solution, and excess liquid ammonia was added to the solution, and the mixture was stirred at 20°C for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure, and the residue was rinsed with water (2mL x 2), and the solid was dried under vacuum to obtain compound 12-5. MS ESI calculated value: C 10 H 15 NO2[M+H] + 182, Actual value: 182.

[0251] Step 5: Synthesis of compound 12-6

[0252] Under the protection of nitrogen gas at 0°C, trifluoroacetic anhydride (417.21mg, 1.99mmol, 276.30μL) was added dropwise to a solution of compound 12-5 (0.18g, 993.21μmol) and triethylamine (502.51mg, 4.97mmol, 691.21μL) in dichloromethane (5mL), and after completion of the addition, the mixture was stirred at 0°C for 30 minutes. After completion of the reaction, saturated sodium bicarbonate (30mL) was added to the reaction solution, extracted with dichloromethane (15mL×3), and the combined organic phase was washed with saturated saline (20mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound 12-6. MS ESI calculated value: C 10 H 13 NO [M + H] + 164, Actual value: 164.

[0253] Step 6: Synthesis of compound 12-7

[0254] Under the protection of nitrogen gas at 0°C, a solution of diethyl cyanomethylphosphonate (119.38mg, 673.95μmol, 108.53μL) in tetrahydrofuran (6mL) was added dropwise to a solution of 1M potassium tert-butoxide (1M, 673.95μL) in tetrahydrofuran. After the completion of the addition, the temperature was raised to 20°C, stirred for 20 minutes, and further cooled to 0°C. A solution of compound 12-6 (0.1g, 612.69μmol) in tetrahydrofuran (2mL) was added dropwise to the solution. After the completion of the addition, the temperature was raised to 20°C, and stirred for 1 hour. After completion of the reaction, the reaction material was poured into water (50 mL), the resulting aqueous solution was extracted with ethyl acetate (10 mL × 3), the combined extracted solution was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane:methanol = 50:1) to obtain compound 12-7. 1 H NMR(400MHz , CDCl3)δ 5.15-5.20 (m, 1 H), 2.90 (s, 1 H), 2.85 (s, 1 H), 2.50-2.75 (m, 4 H), 1.75-1.90 (m, 4 H).

[0255] Step 7: Synthesis of Compounds 12 and 13

[0256] Under the protection of nitrogen gas, a solution of compound 12-7 (80 mg, 429.52 μmol), compound 6-3 (113.94 mg, 429.52 μmol) and DBU (98.08 mg, 644.29 μmol, 97.11 μL) in acetonitrile (3 mL) was heated to 66 ° C and stirred for 6 hours. After the reaction was completed, the reactants were concentrated and the residue was separated by preparative HPLC (separation column model: Welch × timate C18 150 × 30 mm × 5 μm; mobile phase: [water (0.225% formic acid)-acetonitrile]; B (acetonitrile) %: 40% ~ 50%, 8 min) to obtain the racemate. The racemate was separated by chiral separation (chiral column model: DAICEL CHIRALPAK AD (250 mm × 30 mm, 10 μm); mobile phase: A: CO2, B: 0.1% ammonia ethanol, ethanol (0.1% ammonia) and supercritical fluid CO2 50% to 50%, flow rate: 4 mL / min) to obtain compound 12 and compound 13 (analysis method: column model Chiralpak AD-3 50 × 4.6 mm ID, 3 μm; mobile phase: A: CO2, B: ethanol (0.05% diethylamine); gradient: B phase 5% to 40% in 2 min, then 40% held for 1.2 min, and finally 5% held for 0.8 min; flow rate: 4 mL / min; column temperature: 35 °C). The retention times were 2.282 min and 2.566 min, respectively. Compound 12 1 H NMR(400MHz, CD3OD)δ 8.88 (s, 1 H), 8.84 (s, 1 H), 8.46 (s, 1 H), 8.13 (d, J = 2.4 Hz, 1 H), 7.68 (d, J = 2.0 Hz, 1 H), 7.28 (d, J = 2.0 Hz, 1 MS ESI calculation: C 25 H 25 N9[M + H] +452, Measured value: 452. Compound 13 1 H NMR(400MHz , CD3OD)δ 8.88 (s, 1 H), 8.84 (s, 1 H), 8.46 (s, 1 H), 8.13 (d, J = 2.4 Hz, 1 H), 7.68 (d, J =2.4 Hz, 1 H), 7.28 (d, J = 2.4 Hz, 1 MS ESI calculation value: C 25 H 25 N9[M + H] + 452, Actual value: 452.

[0257] Examples 14 and 15

[0258] [ka]

[0259] Synthesis scheme:

[0260] [ka]

[0261] Step 1: Synthesis of compound 14-2

[0262] Compound 14-1 (5 g, 22.14 mmol) was dissolved in tetrahydrofuran (80 mL), sodium hydride (1.33 g, 33.21 mmol, 60% purity) was added in batches at 0° C., and the mixture was stirred at the temperature for 30 minutes. Then, iodomethane (4.08 g, 28.78 mmol, 1.79 mL) was added dropwise at 0° C., and the mixture was reacted at 20° C. for 2 hours. The reaction was quenched by adding saturated aqueous ammonium chloride solution (100 mL), diluted with 100 mL of water, and extracted with ethyl acetate (100 mL×2). The organic layers were combined and washed with 100 mL of brine, dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by silica gel column (petroleum ether:ethyl acetate=10:1) to obtain compound 14-2. 1 H NMR (400 MHz, CDCl3) δ 6.29 (s, 1H), 3.85 (s, 3H).

[0263] Step 2: Synthesis of compound 14-3

[0264] At -65°C, n-butyllithium (2.5M, 8.68mL) was added dropwise to a solution of 14-2 (4.34g, 18.09mmol) in tetrahydrofuran (80mL), and after completion of the addition, the mixture was reacted at the temperature for 0.5 hours. Then, dry ice (20g) was added at -65°C, and the mixture was reacted at -65°C for 30 minutes. The reaction mixture was quenched to pH=4 by adding 1M aqueous hydrochloric acid, then diluted with 200mL water, extracted with ethyl acetate (100mL×2), the organic layers were combined, washed with 100mL brine, dried over sodium sulfate, and purified by silica gel column (petroleum ether:ethyl acetate=10:1 to 1:1) to obtain compound 14-3. 1 HNMR (400 MHz, CDCl3) δ 10.61 (brs, 1 H), 6.96 (s, 1 H), 4.19 (s, 3 H).

[0265] Step 3: Synthesis of compound 14-4

[0266] Compound 14-3 (2.47 g, 12.05 mmol) was dissolved in tert-butyl alcohol (40 mL), diphenylphosphoryl azide (3.98 g, 14.46 mmol, 3.13 mL) and diisopropylethylamine (3.11 g, 24.10 mmol, 4.20 mL) were added, and the mixture was stirred at 45° C. for 0.5 hours, then heated to 100° C. and reacted for 16 hours. The reaction mixture was diluted with 200 mL of water, extracted with 200 mL of ethyl acetate, and the organic layers were combined, washed with saturated aqueous sodium bicarbonate solution (100 mL×2) and 100 mL of brine, dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by silica gel column (petroleum ether:ethyl acetate=30:1 to 10:1) to obtain compound 14-4. 1 HNMR (400 MHz, CDCl3) δ 6.55 (brs, 1 H), 6.18 (s, 1 H), 3.71 (s, 3 H), 1.50 (s, 9 H).

[0267] Step 4: Synthesis of compound 14-5

[0268] 14-4 (2.5 g, 9.05 mmol) was dissolved in dichloromethane (40 mL), 4-dimethylaminopyridine (221.22 mg, 1.81 mmol), di-tert-butyl dicarbonate (3.95 g, 18.11 mmol, 4.16 mL) and triethylamine (2.75 g, 27.16 mmol, 3.78 mL) were added and reacted at 20 ° C for 16 hours. The reaction mixture was diluted with 200 mL of water and extracted with dichloromethane (100 mL × 2), the combined organic layers were washed with 100 mL of brine, dried over sodium sulfate, filtered, concentrated under reduced pressure and purified by silica gel column (petroleum ether / ethyl acetate = 1 / 0 ~ 10 / 1) to obtain compound 14-5. 1 HNMR (400 MHz, CDCl3) δ 6.14 (s, 1 H), 3.65 (s, 3 H), 1.45 (s, 18 H).

[0269] Step 5: Synthesis of compound 14-6

[0270] 14-5 (597.48 mg, 1.59 mmol), bis(pinacolato)diboron (604.89 mg, 2.38 mmol), Xphos-Pd-G2 (124.95 mg, 158.80 μmol) and potassium acetate (389.62 mg, 3.97 mmol) were added to dioxane (15 mL), purged with nitrogen gas three times, and stirred in a nitrogen gas atmosphere at 65 ° C for 4 hours. Next, it was cooled to 20 ° C, and Xphos-Pd-G2 (124.95 mg, 158.80 μmol), potassium phosphate (842.72 mg, 3.97 mmol), 1-12 (0.3 g, 794.01 μmol), and water (2 mL) were added, and the reaction was carried out in a nitrogen gas atmosphere at 90 ° C for 3 hours. The reaction mixture was diluted with 80 mL of water and extracted with ethyl acetate (60 mL × 2), the combined organic layers were washed with 60 mL of brine, dried over sodium sulfate, and purified by silica gel column (petroleum ether: ethyl acetate = 10: 1 to 1: 1) to give compound 14-6. MS ESI calculated value: C 33 H 38 N 10 O4[M + H] + 639, Actual value: 639.

[0271] Step 6: Synthesis of compounds 14 and 15

[0272] 14-6 (0.22 g, 308.96 μmol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (13.51 mmol, 1 mL) was added, and the mixture was stirred at 20 °C for 3 h. The reactants were concentrated under reduced pressure and purified and separated by high performance liquid chromatography (column model: Shim-pack C18 150 × 25 × 10 μm; mobile phase: [water (0.225% formic acid)-acetonitrile]; B (acetonitrile) %: 23%-43%, 9 min) and chiral separation (chiral column model: DAI CEL CHIRALPAK IG (250 mm × 30 mm × 10 μm); mobile phase: [0.1% ammonia / methanol]; B (methanol) %: 50%-50%, 9.7; 110 min), to give compounds 14 and 15, respectively (analysis method: column model Chiralpak IG-3 50 × 4.6 mm ID, 3 μm; Mobile phase: A: CO2, B: methanol + acetonitrile (0.05% diethylamine); Gradient: B phase 60% methanol + acetonitrile (0.05% diethylamine); Flow rate: 3 mL / min; Column temperature: 35° C. The retention times were 2.453 and 3.274 min, respectively. Compound 14: 1 HNMR (400 MHz, DMSO-d6) δ 8.73 (s, 2H), 8.38 (s, 1H), 8.21 (d, J = 2.4 Hz, 1H), 7.43 (d, J = 1.6 Hz, 1H), 6.01 (s, 1H), 5.36 (s, 2H), MS ESI calculated value: C 23 H 22 N 10 [M + H]+ 439, Found: 439. Compound 15: 1HNMR (400 MHz, DMSO-d6) δ 8.73 (s, 2H), 8.38 (s, 1H), 8.21 (d, J = 2.4 Hz, 1H), 7.43 (d, J = 1.6 Hz, 1H), 6.01 (s, 1H), 5.35 (s, 2H), 3.61 (s, 3H), 3.21-3.29 (m, 3H), 2.90-3.04 (m, 2H), 2.57-2.66 (m, 3H), 2.53 (s, 1H), 2.30-2.42 (m, 2H). MS ESI calculation: C 23 H 22 N 10 [M+H]+ 439, Found: 439.

[0273] Examples 16 and 17

[0274] [ka]

[0275] Synthesis scheme:

[0276] [ka]

[0277] Step 1: Synthesis of compound 16-2

[0278] 16-1 (20 g, 63.41 mmol) was added to trifluoroacetic acid (61.60 g, 540.24 mmol, 40.00 mL) at 0° C. and reacted for 2 hours at 0° C. The reaction solution was poured into ice water (200 mL) and filtered to obtain a white precipitate, which was then washed with water (100 mL) to obtain compound 16-2.

[0279] Step 2: Synthesis of compound 16-3

[0280] At 0° C., 16-2 (13.09 g, 60.81 mmol) was dissolved in dichloromethane (80 mL), 3,5-dichloropyridine (6 g, 40.54 mmol) was added, and the mixture was stirred for 16 hours at 15° C. A white solid was precipitated, filtered, and the cake was dried in vacuum to obtain compound 16-3. 1 HNMR (400 MHz, CD3OD) δ 8.93 (d, J = 1.6 Hz, 2H), 8.56 (t, J = 1.6 Hz, 1H), 6.87 (s, 2H), 2.61 (s, 6 H), 2.24 (s, 3H).

[0281] Step 3: Synthesis of compound 16-4

[0282] Compound 16-3 (10.56 g, 29.07 mmol) was dissolved in dimethylformamide (120 mL), and silver carbonate (8.02 g, 29.07 mmol) and ethyl propionate (2.85 g, 29.07 mmol, 2.85 mL) were added, followed by stirring for 16 hours at 30 to 40° C. The reaction mixture was concentrated under reduced pressure and purified using a silica gel column (petroleum ether:ethyl acetate=50:1 to 0:1) to obtain compound 16-4. 1 HNMR (400 MHz, CDCl3) δ 8.50 (s, 1H), 7.23-7.27 (m, 2H), 4.49 (q, J = 7.2 Hz, 2H), 1.46 (t, J = 7.2 Hz, 3H).

[0283] Step 4: Synthesis of compound 16-5

[0284] Compound 16-4 (2.05 g, 7.91 mmol) was added to an aqueous hydrobromic acid solution (45.82 g, 226.51 mmol, 30.75 mL, 40% purity) and reacted at 100° C. for 16 hours. After cooling to room temperature, 60 mL of water was added to precipitate, which was then filtered and the cake was dried and purified with a silica gel column (petroleum ether: ethyl acetate = 20:1 to 0:1) to obtain compound 16-5. 1HNMR (400 MHz, CDCl3) δ 8.47 (s, 1H), 7.98 (d, J = 2.0 Hz, 1H), 7.18 (d, J = 1.6 Hz, 1H), 6.69 (d, J = 1.6 Hz, 1H).

[0285] Step 5: Synthesis of compound 16-6

[0286] Compound 16-5 (0.1 g, 534.69 μmol), compound 1-6 (207.17 mg, 588.15 μmol), potassium phosphate (340.49 mg, 1.60 mmol), tri-tert-butylphosphine palladium (27.33 mg, 53.47 μmol) were added to dioxane (3 mL) and water (0.8 mL), substituted with nitrogen gas three times, and reacted in a nitrogen gas atmosphere at 30 to 40 ° C for 16 hours. The reaction system was quenched by adding saturated ammonium chloride aqueous solution (3 mL), then diluted with 20 mL of water, extracted with ethyl acetate (20 mL × 2), and the organic layers were combined and washed with 20 mL of brine, dried over sodium sulfate, and purified by silica gel column (petroleum ether: ethyl acetate = 10: 1 to 2: 1) to obtain compound 16-6. 1 HNMR (400 MHz, CDCl3) δ 8.48 (s, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.96 (s, 2H), 7.17 (d, J = 2.0 Hz, 1H), 6.72 (dd, J = 0.8, 2.4 Hz, 1H), 3.06-3.15 (m, 1H), 3.02 (s, 3H), 2.94 (d, J = 14.0 Hz, 1H), 2.71-2.81 (m, 2H), 2.66 (m, 2H), 2.44-2.52 (m, 2H).

[0287] Step 6: Synthesis of compounds 16 and 17

[0288] Compound 16-6 (0.15 g, 398.05 μmol), 1-methyl-4-pyrazoleboronic acid pinacol ester (99.38 mg, 477.65 μmol), Xphos-Pd-G2 (36.08 mg, 39.80 μmol), potassium phosphate (253.47 mg, 1.19 mmol) were added to dioxane (4 mL) and water (0.8 mL), the atmosphere was replaced with nitrogen gas three times, and the mixture was stirred at 100° C. for 16 hours in a nitrogen gas atmosphere. The reaction mixture was diluted with 60 mL of water and extracted with ethyl acetate (30 mL x 2), the combined organic layers were washed with 30 mL of brine, dried over sodium sulfate, and purified by silica gel column (petroleum ether:ethyl acetate = 5:1 to 0:1), and then separated by chiral separation (column model: DAICEL CHIRALPAK AD (250 mm x 30 mm x 10 μm); mobile phase: [0.1% ammonia / ethanol]; B (ethanol)%: 40% to 40%, 3.8 min; 60 min) to obtain compound 16 and compound 17 (analytical method: column model Chiralpak AD-3 50 x 4.6 mm ID, 3 μm; mobile phase: A: CO2, B: ethanol (0.05% diethylamine); gradient: B phase: 40% ethanol (0.05% diethylamine); flow rate: 3 mL / min; column temperature: 35 °C). The retention times were 2.270 min and 2.754 min, respectively. Compound 16 1 HNMR (400 MHz, DMSO-d6) δ 8.91 (s, 1H), 8.58 (s, 1H), 8.31 (s, 1H), 8.26 (s, 1H), 8.07 (s, 1H), 8.05 (d, J = 2.4 Hz, 1H), 7.75 (d, J = 1.6 Hz, 1H), 7.00 (dd, J = 0.8, 2.4 Hz, 1H), 3.89 (s, 3H), 3.26-3.31 (m, 3H), 2.89-2.98 (m, 2H), 2.51-2.67 (m, 4H), 2.31-2.42 (m, 2H).MS ESI calculation value:C 24 H 22 N8[M + H] + 423, Measured value: 423. Compound 17 1HNMR(400 MHz, DMSO-d6) δ 8.91 (s, 1H), 8.59 (s, 1H), 8.31 (s, 1H), 8.26 (s, 1H), 8.07 (s, 1H), 8.05 (d, J = 2.0 Hz, 1H), 7.75 (s, MS ESI calculation value:C 24 H 22 N8[M + H] + 423, Actual value: 423.

[0289] Examples 18 and 19

[0290] [ka]

[0291] Synthesis scheme:

[0292] [ka]

[0293] Step 1: Synthesis of compound 18-2

[0294] Compound 18-1 (2.0 g, 14.27 mmol) was added to acetonitrile (20 mL), N-iodosuccinimide (3.53 g, 15.70 mmol) and trifluoroacetic acid (488.18 mg, 4.28 mmol, 317.00 μL) were added, and the mixture was stirred at 80 ° C for 2 hours. After the reaction was completed, the reaction solution was concentrated to obtain a residue, which was diluted with ethyl acetate (100 mL), washed with brine (100 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 1: 0 to 50: 1) to obtain compound 18-2. 1H NMR (400 MHz, CDCl3) δ 7.56 (s, 1H), 4.19 (s, 3H), 3.94 (s, 3H).

[0295] Step 2: Synthesis of compound 18-3

[0296] Compound 18-2 (2.0 g, 7.52 mmol), compound bis(pinacolato)diboron (3.82 g, 15.04 mmol), [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (550.08 mg, 751.78 μmol) and potassium acetate (2.21 g, 22.55 mmol) were added to dimethyl sulfoxide (30 mL) and stirred at 100 °C for 1 h under the protection of nitrogen gas. After the reaction was completed, the reaction solution was diluted with ethyl acetate (100 mL), washed with brine (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 100: 1 to 5: 1) to obtain compound 18-3. MS ESI calculated value: C 12 H 19 BN2O4[M + H] + 267, Actual value: 267.

[0297] Step 3: Synthesis of compound 18-4

[0298] A mixture of compound 18-3 (704.29 g, 2.65 mmol), compound 1-12 (0.50 g, 1.32 mmol), Xphos-Pd-G2 (104.12 mg, 132.33 μmol) and potassium phosphate (842.71 mg, 3.97 mmol) was added with dioxane (8 mL) and water (2 mL) and stirred at 100 °C for 16 hours under the protection of nitrogen gas. After the reaction was completed, the reaction solution was diluted with ethyl acetate (50 mL), washed with brine (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 4: 1 to 1: 3) to obtain compound 18-4. MS ESI calculated value: C 25 H 23NO2[M + H] + 482, Actual value: 482.

[0299] Step 4: Synthesis of compound 18-5

[0300] A solution of lithium hydroxide (38.20 g, 1.59 mmol) in water (0.5 mL) was added dropwise to a solution of compound 18-4 (0.4 g, 797.49 mmol) in methanol (10 mL), and the mixture was stirred at 20° C. for 16 hours. After completion of the reaction, the reaction solution was adjusted to pH 3-4 with 0.5 M hydrochloric acid and concentrated to give a residue, which was diluted with dichloromethane (10 mL) and methanol (1 mL), filtered, and the filtrate was concentrated to give compound 18-5. MS ESI calculated value: C 24 H 21 NO2[M + H] + 468, Actual value: 468.

[0301] Step 5: Synthesis of compound 18-6

[0302] A solution of compound 18-5 (0.4 g, 658.85 mmol), diphenylphosphoryl azide (271.97 mg, 998.27 μmol, 214.15 μL) and N,N-diisopropylethylamine (127.73 mg, 998.27 μmol, 172.14 μL) in tert-butyl alcohol (10 mL) was stirred under nitrogen gas protection at 60 °C for 0.5 h, and then at 100 °C for 1.5 h. After the reaction was completed, the reaction solution was diluted with ethyl acetate (10 mL), washed with saturated aqueous sodium bicarbonate solution (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The obtained crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3: 1 to 1: 3) to obtain compound 18-6. MS ESI calculated value: C 28 H 30 N 10 O2[M + H] + 539, Actual value: 539.

[0303] Step 6: Synthesis of compound 18-7

[0304] Compound 18-6 (0.3 g, 537.50 mmol) was added to anhydrous dichloromethane (10 mL), trifluoroacetic acid (4.62 g, 40.52 mmol, 3 mL) was added, and the mixture was stirred at 30 ° C for 1 hour. After the reaction was completed, the reaction solution was concentrated, ethyl acetate (10 mL) was added to the reaction solution to dilute it, ammonia water (30% purity, 1 mL) was added, and the mixture was concentrated to obtain a residue, which was then subjected to prep-HPLC (column model: Waters Xbridge 150 × 25 mm × 5 μm; mobile phase: [H2O (10 mM NH4HCO3)-ACN]; ACN%: 18% to 48%, 9 min) to obtain compound 18-7. MS ESI calculated value: C 23 H 22 N 10 [M + H] + 439, Actual value: 439.

[0305] Step 7: Synthesis of Compound 18 and Compound 19

[0306] Compound 18-7 was separated by chiral separation (chiral column model: DAICEL CHIRALPAK AD (250 mm × 30 mm × 10 μm); mobile phase: [0.1% NH3H2O ​​IPA]; B (IPA)%: 40% to 40%, 4.5 min; 70 min), and then compound 18 and compound 19 were obtained (analysis method: column model Chiralpak AD-3 50 × 4.6 mm ID, 3 μm; mobile phase: A: CO2, B: isopropyl (0.05% diethylamine); gradient: B phase 40% isopropyl (0.05% diethylamine); flow rate: 3 mL / min; column temperature: 35 °C). The retention times were 1.099 min and 1.422 min, respectively. Compound 18, 11H NMR (400 MHz, DMSO-d6) δ 8.87 (s, 1H), 8.73 (s, 1H), 8.34 (s, 1H), 8.14 (d, J = 2.4 Hz, 1H), 7.85 (s, 1H), 7.37 (d, J = 1.8 Hz, 1H), 6.04 (s, 2H), 3.61 (s, 3H), 3.32 - 3.35 (m, 2H), 3.23 - 3.31 (m, 1H), 2.93 - 3.03 (m, 2H), 2.52 - 2.68 (m, 4H), 2.30 - 2.41 (m, 2H). MS ESI calculated value: C 23 H 22 N 10 [M + H] + 439, found: 439. Compound 19, 1 1H NMR (400 MHz, DMSO-d6) δ 8.87 (s, 1H), 8.74 (s, 1H), 8.34 (s, 1H), 8.15 (d, J = 2.4 Hz, 1H), 7.85 (s, 1H), 7.38 (d, J = 1.8 Hz, 1H), 6.05 (s, 2H), 3.62 (s, 3H), 3.36 - 3.34 (m, 2H), 3.23 - 3.30 (m, 1H), 2.93 - 3.04 (m, 2H), 2.53 - 2.68 (m, 4H), 2.30 - 2.43 (m, 2H). MS ESI calculated value: C 23 H 22 N 10 [M + H] + 439, found: 439.

[0307] Examples 20 and 21

[0308]

Chemical Structure

[0309] Synthesis Scheme:

[0310]

Chemical Structure

[0311] Step 1: Synthesis of compound 20-2

[0312] Compound 20-1 (10 g, 44.27 mmol) and 3,4-dihydro-2H-pyran (14.90 g, 177.09 mmol, 16.19 mL) were added with trifluoroacetic acid (50.48 mg, 442.73 μmol, 32.78 μL), and the mixture was stirred at 100° C. for 16 h. The reaction was diluted with 60 mL of n-heptane, stirred at 20° C. for 0.5 h, filtered, and dried in vacuum to give compound 20-2. 1 HNMR (CDCl3) δ 6.36 (s, 1H), 5.43 (dd, J = 9.6, 2.8 Hz, 1H), 3.96-4.13 (m, 1H), 3.67 (td, J = 11.2, 2.8 Hz, 1H), 2.35-2.47 (m, 1H), 2.07-2.18 (m, 1H), 1.85-1.97 (m, 1H), 1.56-1.75 (m, 3H).

[0313] Step 2: Synthesis of compound 20-3

[0314] Compound 20-2 (5.68 g, 18.32 mmol) was dissolved in tetrahydrofuran (100 mL), and n-butyl lithium (2.5 M, 8.80 mL) was added dropwise at -65 ° C. After completion of the addition, the mixture was stirred at the same temperature for 0.5 hours, and then dry ice (20 g) was added at -65 ° C. and stirred for 30 minutes. The reaction system was quenched by adding 1 M aqueous hydrochloric acid solution, adjusted to pH = 4, diluted with 200 mL of water, extracted with ethyl acetate (100 mL x 2), and the organic layers were combined and washed with 100 mL of brine (100 mL x 1), dried over sodium sulfate, and purified by silica gel column (petroleum ether: ethyl acetate = 10: 1 to 1: 1) to obtain compound 20-3. 1HNMR (DMSO-d6) δ 13.84 (brs, 1H), 6.99 (s, 1H), 6.16 (dd, J = 10.0, 2.4 Hz, 1H), 3.84-3.97 (m, 1H), 3.50-3.57 (m, 1H), 2.10-2.27 (m, 1H), 1.95 (m, 1H), 1.80-1.91 (m, 1H), 1.56-1.72 (m, 1H), 1.46-1.56 (m, 2H).

[0315] Step 3: Synthesis of compound 20-4

[0316] Compound 20-3 (3.4 g, 12.36 mmol) was dissolved in tert-butyl alcohol (40 mL), diphenylphosphoryl azide (6.80 g, 24.72 mmol, 5.36 mL) and triethylamine (3.19 g, 24.72 mmol, 4.31 mL) were added, and the mixture was stirred at 45 ° C for 0.5 h, and then heated to 100 ° C for 16 h. The reaction mixture was diluted with 200 mL of water, extracted with ethyl acetate (100 mL × 2), and the organic layers were combined and washed with saturated aqueous sodium bicarbonate solution (100 mL × 2) and 100 mL of brine, dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by silica gel column (petroleum ether: ethyl acetate = 30: 1 to 10: 1) to obtain compound 20-4. 1 HNMR (CDCl3) δ 7.41 (brs, 1H), 6.39 (s, 1H), 5.37 (dd, J = 8.0, 2.8 Hz, 1H), 3.92 (dt, J = 11.2, 3.6 Hz, 1H), 3.69 (dt, J = 12.0, 6.0 Hz, 1H), 2.15-2.35 (m, 1H), 2.04-2.09 (m, 1H), 1.59-1.67 (m, 4H), 1.52 (s, 9H).

[0317] Step 4: Synthesis of compound 20-5

[0318] Compound 20-4 (5.78 g, 9.18 mmol) was dissolved in dichloromethane (40 mL), and 4-dimethylaminopyridine (224.35 mg, 1.84 mmol), di-tert-butyl dicarbonate (4.01 g, 18.36 mmol, 4.22 mL) and triethylamine (2.79 g, 27.55 mmol, 3.83 mL) were added. The mixture was stirred at 20 °C for 16 h. The reaction mixture was diluted with 200 mL of water and extracted with dichloromethane (100 mL × 2), and the combined organic layers were washed with 100 mL of brine, dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by silica gel column (petroleum ether: ethyl acetate = 1: 0 to 10: 1) to give compound 20-5. 1 HNMR (CDCl3) δ 6.16 (s, 1H), 5.12 (dd, J = 9.6, 2.8 Hz, 1H), 3.93-4.01 (m, 1H), 3.55 (td, J = 11.2, 2.4 Hz, 1H), 2.29-2.43 (m, 1H), 2.05-2.15 (m, 1H), 1.76-1.91 (m, 1H), 1.53-1.70 (m, 3H), 1.41 (s, 18H).

[0319] Step 5: Synthesis of compounds 20-6 and 21-6

[0320] Compound 20-5 (472.53 mg, 1.06 mmol), bis(pinacolato)diboron (403.26 mg, 1.59 mmol), Xphos-Pd-G2 (83.30 mg, 105.87 μmol) and potassium acetate (259.75 mg, 2.65 mmol) were added to dioxane (10 mL) and stirred at 65 ° C. for 3 hours under nitrogen gas atmosphere, then cooled to 20 ° C. Xphos-Pd-G2 (83.30 mg, 105.87 μmol), potassium phosphate (561.81 mg, 2.65 mmol), 1-12 (0.2 g, 529.34 μmol) and water (2 mL) were added and stirred at 90 ° C. for 16 hours under nitrogen gas atmosphere. The reaction solution was added with 80 mL of water, extracted with ethyl acetate (60 mL × 2), the organic layers were combined and washed with brine (60 mL × 1), dried over sodium sulfate, and purified by silica gel column (petroleum ether: ethyl acetate = 5: 1 to 1: 1) and high performance liquid chromatography (column model: Phenomenex Luna C18 150 × 25 mm × 10 μm; mobile phase: [water (0.225% formic acid)-acetonitrile]; acetonitrile%: 56% to 86%, 11 min), and then SFC (column model: DAICEL CHIRALPAKIE (250 mm × 30 mm, 10 μm); mobile phase: [0.1% ammonia / ethanol]; [0.1% ammonia / ethanol]%: 50% to 50%, 11.0 min; 77 min) to obtain compounds 20-6 and 21-6 (analysis method: column type Chiralpak ID-3 100 × 4.6 mm ID, 3 μm; Mobile phase: A: n-heptane (0.05% diethylamine), B: ethanol (0.05% diethylamine); Gradient: 40% B phase; Flow rate: 1 mL / min; Column temperature: 35° C. The retention times were 4.703 and 6.547 min, respectively. MS ESI calculated for compound 20-6: C 37 H 44 N 10 O5 [M + H] + 709, Found: 709. MS ESI calculated value for compound 21-6: C 37 H 44 N 10 O5 [M + H] + 709, Actual value: 709.

[0321] Step 6: Synthesis of compound 20

[0322] Compound 20-6 (60 mg, 84.65 μmol) was dissolved in dichloromethane (1 mL), trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL) was added, and the mixture was stirred at 25° C. for 0.5 hours. The reaction mixture was concentrated under reduced pressure and purified by high performance liquid chromatography (column model: Waters Xbridge 150×25 mm×5 μm; mobile phase: [0.01% aqueous ammonium bicarbonate solution-acetonitrile]; acetonitrile%: 11% to 41%, 10 min) to obtain compound 20. 1 HNMR (DMSO-d6) δ 12.15 (s, 1H), 9.08 (s, 1H), 8.99 (s, 1H), 8.62 (s, 1H), 8.24 (d, J = 2.4 Hz, 1.2H), 7.50 (s, 1H), 6.14 (s, 1H), MS ESI calculated value: C 22 H 20 N 10 [M + H] + 425, Actual value: 425.

[0323] Step 7: Synthesis of compound 21

[0324] Compound 21-6 (70 mg, 98.76 μmol) was dissolved in dichloromethane (1 mL), trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL) was added, and the mixture was stirred at 25° C. for 0.5 hours. The reaction mixture was concentrated under reduced pressure and purified by high performance liquid chromatography (column: Waters Xbridge 150×25 mm×5 μm; mobile phase: [0.01% aqueous ammonium bicarbonate solution-acetonitrile]; acetonitrile%: 11% to 41%, 10 min) to obtain compound 21. 1HNMR (DMSO-d6) δ: 12.10 (brs, 1H), 8.86-9.17 (m, 2H), 8.59 (s, 1H), 8.24 (d, J = 2.4 Hz, 2H), 7.50 (d, J = 1.6 Hz, 1H), 6.12 (s, 1H), 4.58-4.99 (m, 2H), 3.25-3.34 (m, 3H), 2.97 (td, J = 14.6, 1.6 Hz, 2H), 2.58-2.69 (m, 3H), 2.52-2.56 (m, 1H), 2.30-2.43 (m, 2H).MS ESI calculation value:C 22 H 20 N 10 [M + H] + 425, Actual value: 425.

[0325] Biological activity test Experimental example 1: In vitro activity test of Jak1, Jak2, Jak3, and Tyk2 kinases Experimental materials Recombinant human JAK1, JAK2, JAK3 and Tyk2 proteases, key equipment and reagents were all provided by Eurofins, UK. Experimental Method JAK2, JAK3 and TYK2 dilutions: 20 mM 3-(N-morpholine)propanesulfonic acid (MOPS), 1 mM EDTA, 0.01% Brij-3 5.5% glycerol, 0.1% β-mercaptoethanol, 1 mg / mL BSA; JAK1 dilutions: 20 mM TRIS, 0.2 mM EDTA, 0.1% β-mercaptoethanol, 0.01% Brij-3 5.5% glycerol. All compounds were prepared in 100% DMSO at 50x the final test concentration. Test compounds were diluted 3-fold in nine concentrations ranging from 10 μM to 0.001 μM final concentration, and the DMSO content in the detection reaction was 2%. The working stock solution of the compound was added to the test well as the first component of the reaction, followed by the addition of the remaining components according to the detailed protocol of the test below.

[0326] JAK1(h) enzyme reaction JAK1(h) was incubated with 20 mM Tris / HCl pH 7.5, 0.2 mM EDTA, 500 μM MGEEPLYWSFPAKKK, 10 mM magnesium acetate, and [γ- 33 The reaction was incubated with [P]-ATP (activity and concentration adjusted as necessary). The reaction was initiated by the addition of the Mg / ATP mix and after 40 min incubation at room temperature, the reaction was stopped by the addition of 0.5% phosphoric acid. 10 μL of the reaction was then spotted onto a P30 filter pad, washed three times with 0.425% phosphoric acid and once with methanol within 4 min, dried, and scintillation counted.

[0327] JAK2(h) enzyme reaction JAK2(h) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 100 μM KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC, 10 mM magnesium acetate, and [γ- 33 The reaction was incubated with [P]-ATP (activity and concentration adjusted as necessary). The reaction was initiated by the addition of the Mg / ATP mix and after 40 min incubation at room temperature, the reaction was stopped by the addition of 0.5% phosphoric acid. 10 μL of the reaction was then spotted onto a P30 filter pad, washed three times with 0.425% phosphoric acid and once with methanol within 4 min, dried, and scintillation counted.

[0328] JAK3(h) enzyme reaction JAK3(h) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 500 μM GGEEEEYFELVKKKK, 10 mM magnesium acetate, and [γ- 33 The reaction was incubated with [P]-ATP (activity and concentration adjusted as necessary). The reaction was initiated by the addition of the Mg / ATP mix and after 40 min incubation at room temperature, the reaction was stopped by the addition of 0.5% phosphoric acid. 10 μL of the reaction was then spotted onto a P30 filter pad, washed three times with 0.425% phosphoric acid and once with methanol within 4 min, dried, and scintillation counted.

[0329] TYK2(h) enzyme reaction TYK2(h) and 8 mM MOPS pH 7.0, 0.2 mM EDTA, 250 μM GGMEDIYFEFMGGKKK, 10 mM magnesium acetate, and [γ- 33 The reaction was incubated with [P]-ATP (activity and concentration adjusted as necessary). The reaction was initiated by the addition of the Mg / ATP mix and after 40 min incubation at room temperature, the reaction was stopped by the addition of 0.5% phosphoric acid. 10 μL of the reaction was then spotted onto a P30 filter pad, washed three times with 0.425% phosphoric acid and once with methanol within 4 min, dried, and scintillation counted.

[0330] Data analysis I C 50 The results were analyzed by IDBS's XLFIT5 (205 formula), and are shown in Table 7 below.

[0331] Table 7. In vitro screening test results for compounds of the present invention

[0332] [Table 7]

[0333] Conclusion: The compounds of the present invention showed good selective inhibition against TYK2 and / or JAK1 and / or JAK2 in in vitro activity tests of four kinase subtypes JAK1, JAK2, JAK3 and TYK2.

[0334] Experimental example 2: Pharmacokinetic (PK) study The clear solution obtained after dissolving the test compound was injected into male mice (BALB / C) via tail vein and intragastric administration, respectively. After administration of the test compound, blood was collected from the submandibular vein at 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours for the intravenous injection group (1 mg / kg) and at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours for the intragastric injection group (3 mg / kg), respectively, and centrifuged to obtain plasma. Blood drug concentrations were measured using LC-MS / MS method, and related pharmacokinetic parameters were calculated using the non-compartmental model linear logarithmic ladder method using WinNonlin™ Version 6.3 pharmacokinetic software. The measurement results are shown in Table 8.

[0335] Table 8. PK study results of compound 1 in mice

[0336] [Table 8]

[0337] Note: T 1 / 2 : Half-life; C max : peak concentration; Cl: clearance; Vd: volume of distribution; AUC 0-inf : area under the plasma concentration-time curve extrapolated from time zero to infinity;Bioavailability: bioavailability.

[0338] Conclusion: The compounds of the present invention have good oral bioavailability in mice, which is beneficial for producing higher exposure and good in vivo efficacy.

[0339] Experimental Example 3: In vivo drug efficacy test in a mouse psoriasis model Objective: The objective of this experiment was to induce a psoriasis-like skin lesion model by intradermal injection of IL-23 into mouse ears, and to evaluate the preventive and therapeutic effects of test substances on IL-23-induced psoriasis-like skin lesions in mice.

[0340] Methods: After the adaptation period of the experimental animals, 50 mice were divided into 5 groups, 10 mice in each group, according to the complete randomization method in Excel, which were the vehicle (0.5% MC & 0.5% Tween 80) control group, the modeling group, and the compound 1 (10, 20, 50 mg / kg) group, respectively. Except for the vehicle control group, the right ear of the animals in the other groups was intradermally injected with IL-23 (3 μg / 10 μL / mouse / day, QD) for 8 consecutive days (D1-D8), and the right ear of the animals in the control group was intradermally injected with an equal amount of saline (10 μL / mouse / day, QD) for 8 consecutive days (D1-D8). Simultaneously with the modeling, the vehicle and the test drug were orally administered twice a day (Bid), with an interval of 6 hours, for 8 consecutive days (D1-D8). During the administration period, the animals were weighed every 2 days. On D1, D3, D5, D7 (all before IL-23 injection), and D9, the thickness of the right ear of the mice was measured, and the appearance of the pinna was observed and scored. At the end of the experiment (day 10), the modeling side ear was excised, and the earpiece was punched out with an 8 mm punch along the edge of the pinna, weighed, and the right earpiece was fixed in formalin, after which histopathological examination (H&E) staining was performed.

[0341] The experimental results are shown in Tables 9 to 12.

[0342] Table 9. Effect of oral intragastric administration of test substances twice daily for 8 consecutive days on the body weight of IL-23-induced mouse ear epidermal dysplasia model mice

[0343] [Table 9]

[0344] Table 10. Effect of oral intragastric administration of test substances twice daily for 8 consecutive days on ear thickness in IL-23-induced mouse ear epidermal dysplasia model mice

[0345] [Table 10]

[0346] Table 11. Effects of test substances on ear weight in IL-23-induced mouse ear epidermal dysplasia model mice

[0347] [Table 11]

[0348] Table 12. Effect of oral intragastric administration of test substances twice daily for 8 consecutive days on the total score of IL-23-induced mouse ear epidermal dysplasia

[0349] [Table 12]

[0350] NOTE: IL-23: Interleukin-23.

[0351] Conclusion: 1. In the IL-23-induced ear epidermal dysplasia model in C57BL / 6 mice, oral administration of the compounds of the present invention (10, 20, 50 mg / kg) twice daily for 8 consecutive days had no significant effect on the body weight of animals in the IL-23-induced C57BL / 6 mouse ear epidermal dysplasia model.

[0352] 2. Effect on animal modeling lateral ear thickness: Compound 1 at 10 and 20 mg / kg significantly reduced mouse modeling lateral ear thickness from day 5, and the compound of the present invention can significantly reduce animal modeling lateral ear thickness at a dose of 50 mg / kg starting from D3, and the three dose groups showed a good dose-effect relationship. It was shown that each group of the compound of the present invention (10, 20, 50 mg / kg) can inhibit the increase in mouse modeling lateral ear thickness to different degrees.

[0353] 3. Effect on the weight of the animal modeling lateral ear: Oral intragastric administration of the compound of the present invention (10, 20, 50 mg / kg) twice daily for 8 consecutive days could significantly reduce the weight of the animal modeling lateral ear, and all three dosage groups showed a good dose-effect relationship in reducing the weight of the animal modeling lateral ear.

[0354] 4. Effect on animal modeling lateral ear total score: Intragastric administration of the compounds of the present invention (10, 20, 50 mg / kg) twice daily for 8 consecutive days significantly reduced the total score of the affected ear in mice from D5 to D9, showing good efficacy and a good dose-effect relationship.

Claims

1. A compound represented by formula (IV) or a pharma- ceutically acceptable salt thereof. 【Chemistry 1】 (however, R A is selected from H, and R B teeth, 【Chemistry 2】 is selected from Or, R A and R B are the carbon atoms to which they are connected 【Chemistry 3】 Forming Ring A is C 5-8 cycloalkyl; Ring B is C 5-10 cycloalkyl or 5-10 membered heterocycloalkyl; R 1 is H, C 1-3 Alkyl-SO 2 -, CN and -CH 2 CN, wherein C 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; R 2 is H and C 1-3 alkyl, 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; R 3 , H, NH 2 , halogens, OH, CN and C 1-3 alkyl, 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; T 2 is selected from CH and N.

2. Ring A is 【Chemistry 4】 The compound of claim 1 represented by formula (IV) or a pharma- ceutically acceptable salt thereof, selected from:

3. Ring B is 【Chemistry 5】 is selected from L 1 is -(CH 2 ) m -, wherein -(CH 2 ) m - is optionally substituted by 1, 2 or 3 halogens; L 2 is -(CH 2 ) n -, wherein -(CH 2 ) n - is optionally substituted by 1, 2 or 3 halogens; m and n are each independently selected from 1, 2, and 3; T 1 The compound of claim 1 , wherein R is selected from CH and N, or a pharma- ceutically acceptable salt thereof.

4. The compound is selected from the structures represented by formula (IV) or (IIV-2) according to any one of claims 1 to 3, wherein the compound is represented by formula (IV) or a pharma- ceutically acceptable salt thereof. 【Chemistry 6】 (However, R 1 , R 2 , R 3 , T 2 , Ring A and Ring B are as defined in any one of claims 1 to 3.

5. The compound is selected from the structure represented by formula (I): A compound represented by formula (IV) according to claim 1 or a pharma- ceutically acceptable salt thereof. 【Chemistry 7】 (however, R 1 is H, C 1-3 Alkyl-SO 2 -, CN and -CH 2 CN, wherein C 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; R 2 is H and C 1-3 alkyl, 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; R 3 , H, NH 2 , halogens, OH, CN and C 1-3 alkyl, 1-3 The alkyl is optionally substituted with 1, 2 or 3 halogens; L 1 is -(CH 2 ) m -, wherein -(CH 2 ) m - is optionally substituted by 1, 2 or 3 halogens; L 2 is -(CH 2 ) n -, wherein -(CH 2 ) n - is optionally substituted by 1, 2 or 3 halogens; m and n are each independently selected from 1, 2, and 3; T 1 is selected from CH and N; T 2 is selected from CH and N.

6. R 1 is H, C 1-3 Alkyl-SO 2 -, CN and -CH 2 CN, wherein C 1-3 6. The compound of claim 5, wherein the alkyl is optionally substituted with 1, 2 or 3 F, or a pharma- ceutically acceptable salt thereof.

7. R 1 , H, CF 3 SO 2 -, CN and -CH 2 7. The compound of claim 6, wherein the compound is selected from the group consisting of:

8. R 2 is H and CH 3 6. The compound of claim 5, selected from:

9. R 3 is H and NH 2 6. The compound of claim 5, selected from:

10. L 1 is -CH 2 - and -CH 2 CH 2 -, wherein said -CH 2 - and -CH 2 CH 2 6. The compound of claim 5, wherein - is optionally substituted by 1, 2 or 3 F, or a pharma- ceutically acceptable salt thereof.

11. L 1 is -CH 2 - and -CH 2 CH 2 or a pharma- ceutically acceptable salt thereof.

12. L 2 is -CH 2 - and -CH 2 CH 2 -, wherein said -CH 2 - and -CH 2 CH 2 6. The compound of claim 5, wherein - is optionally substituted by 1, 2 or 3 F, or a pharma- ceutically acceptable salt thereof.

13. L 2 is -CH 2 - and -CH 2 CH 2 13. The compound of claim 12, or a pharma- ceutically acceptable salt thereof, selected from:

14. Structural Fragment 【Chemistry 8】 or a pharma- ceutically acceptable salt thereof.

6. The compound of claim 5, wherein: is selected from acridinyl, cyclobutyl, tetrahydropyrrolyl, piperidinyl, and cyclohexyl; or a pharma- ceutically acceptable salt thereof.

15. Structural Fragment 【Chemistry 9】 15. The compound of claim 14, selected from:

16. The compound according to any one of claims 5 to 15, wherein the compound is selected from structures represented by formulas (I-1) and (I-2), or a pharma- ceutically acceptable salt thereof. 【Chemistry 10】 (However, R 1 , R 2 , R 3 , T 1 , T 2 , m and n are as defined in any one of claims 5 to 15.

17. A compound of the formula: or a pharma- ceutically acceptable salt thereof. 【Chemistry 11】

18. 18. The compound of claim 17, wherein the compound is selected from the formula: or a pharma- ceutically acceptable salt thereof. 【Chemistry 12】

19. 20. Use of a compound according to any one of claims 1 to 18, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of psoriasis and / or inflammatory bowel disease.

Citation Information

Patent Citations

  • Pyrrolo pyrimidine compound as selective JAK2 inhibitor, synthetic method and application thereof

    CN110028509A

  • Pyrrole / imidazo six-membered hetero-aromatic ring compound as well as preparation method and medical application thereof

    CN111320633A

  • 5,7-substituted imidazo[1,2-c]pyrimidine as a JAK kinase inhibitor

    JP2013523884A

  • 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors

    JP2018507167A

  • Pyrazolo[1,5-a]pyrazin-4-yl derivatives as JAK inhibitors

    JP2019510003A